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The designations employed and the presentation of the 
material in the Synthetic Drugs and New Psychoactive 
Substances in Latin America and the Caribbean 2021 
report do not imply the expression of any opinion what-
soever on the part of the Secretariat of the United Nations 
concerning the legal status of any country, territory, city 
or area, or of its authorities, or concerning the delimita-
tion of its frontiers or boundaries. 
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral term “drug use” is used in this 
report. The term “misuse” is used only to denote the 
non-medical use of pharmaceutical drugs. 
All uses of the word “drug” and the term “drug use” in this 
report refer to substances controlled under the three 
inter national drug control conventions, and their 
non-medical use. 
All analysis contained in this report is based on the offi-
cial data submitted by Member States to UNODC 
through the annual report questionnaire (up to the 2019 
reporting year) and through the UNODC Early Warning 
Advisory on New Psychoactive Substances (up to 
December 2020, data for 2020 are still preliminary), 
unless indicated otherwise. 
References to tons are to metric tons, unless otherwise 
stated.
The term “region” unless specified, generally refers to the 
geographical area that includes the countries and territo-
ries in Latin America and the Caribbean. Countries and 
areas are referred to by the names that were in official use 
at the time the relevant data were collected. For the pur-
pose of this report, Latin America and the Caribbean 
comprises all countries and territories of the Americas 
with exception of Canada, Greenland, Saint-Pierre and 
Miquelon and the United States of America.
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General abbreviations
 ATS  Amphetamine-type 
stimulants
 CICAD  Comisión Interamericana 
para el Control del Abuso 
de Drogas (Inter-American 
Drug Abuse Control 
Commission)
 DEA   United States Drug 
Enforcement 
Administration 
 EMCDDA   European Monitoring 
Centre for Drugs and Drug 
Addiction
 Europol   European Union Agency 
for Law Enforcement 
Cooperation
 NPS   New psychoactive 
substance(s)
 OAS   Organization of American 
States
 SMART   Global Synthetics 
Monitoring: Analyses, 
Reporting and Trends 
Programme

































 25H-NBOMe  1-(2,5-Dimethoxyphenyl)-
N-[(2-methoxyphenyl)
methyl]ethanamine
 25I-NBOH  2-({[2-(4-iodo-2,5-dimeth-
oxyphenyl)ethyl]amino}
methyl)phenol




 2C-B  2,5-Dimethoxy-4- 
bromophenethylamine
 2C-C  2,5-Dimethoxy-4- 
chlorophenethylamine
 2C-E  2,5-Dimethoxy-4- 
ethylphenethylamine
 2C-I  2,5-Dimethoxy-4- 
iodophenethylamine
 4-AP 4-Anilinopiperidine
 4-APB  4-(2-aminopropyl)
benzofuran
 5-EAPB  1-(Benzofuran-5-yl)-N- 
ethylpropan-2-amine




 5-MAPB  N-Methyl-5- 
(2-aminopropyl) 
benzofuran 
 5-MeO-DIPT  5-Methoxy-N,N- 
diisopropyltryptamine
 5-MeO-MiPT  5-Methoxy-N- 
isopropyl-N-methyl-
tryptamine
 6-APB  6-(2-Aminopropyl)
benzofuran




 alpha-PVP  alpha-Pyrrolidinovale- 
rophenone
 AM-2201  [1-(5-Fluoropentyl)- 
1H-indol-3-yl]-1-
naphthalenyl-methanone 
 ANPP  4-Anilino-N- 
phenethylpiperidine
 APAAN  alpha-Phenyl- 
acetoacetonitrile
 DMT N,N-Dimethyltryptamine
 DOC  2,5-Dimethoxy-4- 
chloroamphetamine
 DOI  2,5-Dimethoxy-4- 
iodoamphetamine




 JWH-018  (1-Pentyl-1H-indol-3-yl)- 
1-naphthalenyl-methanone
 LSD Lysergide
 MDA  3,4-Methylenedioxy- 
amphetamine
 MDMA  3,4-Methylenedioxy- 
methamphetamine
 N-ethyl-MDA  3,4-Methylenedioxy-N- 
ethylamphetamine
x
 NBOMe  Referring to the 
N-benzylmethoxy moiety 
of a compound















Amphetamine-type stimulants: a group of substances com-
posed of synthetic stimulants controlled under the 
Convention on Psychotropic Substances of 1971 and 
from the group of substances called amphetamines, 
which includes amphetamine, methamphetamine, 
 methcathinone and the “ecstasy”-group substances 
(3,4-methyl enedioxymethamphetamine (MDMA) and 
its analogues). 
Amphetamines: a group of amphetamine-type stimulants 
that includes amphetamine and methamphetamine. 
Annual prevalence: the total number of people of a given 
age range who have used a given drug at least once in the 
past year, divided by the number of people of the given 
age range, and expressed as a percentage. 
COVID-19: disease caused by a new coronavirus called 
SARS-CoV-2 (World Health Organization, Coronavirus 
disease (COVID-19) (October 2020)). 
Drug use: use of controlled psychoactive substances for 
non-medical and non-scientific purposes, unless other-
wise specified. 
New psychoactive substances: substances of abuse, either 
in a pure form or a preparation, that are not controlled 
under the Single Convention on Narcotic Drugs of 1961 
or the 1971 Convention, but that may pose a public 
health threat. In this context, the term “new” does not 
necessarily refer to new inventions but to substances that 
have recently become available. For the purpose of the 
report, NPS that have been placed under inter national 
control since 2014 continue to be included under the 
term NPS to enable times series analysis.
Opiates: a subset of opioids comprising the various 
 products derived from the opium poppy plant, including 
opium, morphine and heroin. 
Opioids: a generic term that refers both to opiates and their 
synthetic analogues (mainly prescription or  pharmaceutical 
opioids) and compounds synthesized in the body.
Synthetic drugs: includes any substance of synthetic 
origin with psychoactive effects available on the illicit 
drug market and/or used for non-medical purposes.
Synthetic opioids: include fentanyl, fentanyl analogues 





This report sets focus on trends and changes in Latin 
America and the Caribbean in the field of synthetic drugs 
and new psychoactive substances (NPS) since the last 
regional report, published by UNODC in 2014.1 It is 
meant to complement other publications such as the 
report on Drug Use in the Americas, published by the 
Organization of American States/Inter-American Drug 
Abuse Control Commission (OAS/CICAD), and the 
annual analysis of the UNODC World Drug Report. 
While the regional UNODC report of 2014 gave an over-
view on amphetamine-type stimulants (ATS), only, this 
report covers, apart from the major amphetamine-type 
stimulants, other synthetic drugs of relevance, for example 
hallucinogens and fentanyl, as well as NPS. This is owed 
to the fact that Latin America and the Caribbean, like 
other regions, has experienced a massive expansion and 
diversification of the synthetic drug market and the rapid 
emergence of a wide range of NPS particularly from 2013 
onwards. The structure of the report, which covers not 
only drugs with stimulant effects but also hallucinogens 
and dissociatives, opioids and sedatives/hypnotics pro-
vides evidence of this diversification. For the first time, a 
chapter on the illicit manufacture of synthetic drugs and 
their precursors has been included. 
In terms of regional scope, this report covers Latin 
America and the Caribbean, i.e., all countries in the 
Americas except Canada and the United States of 
America. For seizure statistics, the period 2015 to 2019 
was used, supplemented by more recent official state-
ments or press releases where available. For prevalence of 
use, the most recent estimates were used and compared to 
previous years as appropriate to identify trends. For the 
NPS trend analysis, data available in the UNODC Early 
Warning Advisory on NPS2 from 2009 to 2019 were ana-
lysed and for the description of the overall NPS situation 
all available data as of 31 December 2020 were used. 
1 UNODC, Amphetamine-type Stimulants in Latin America (February 
2014).
2 The UNODC, Early Warning Advisory on NPS may be accessed at 
www.unodc.org/nps.
What has happened since 2014?
In 2014, synthetic drugs were still a niche topic in Latin 
America and the Caribbean, a region which, to date, 
 continues to be dominated by drugs such as cocaine and 
cannabis both in terms of production and use. 
However, changes in the manufacturing of methampheta-
mine, which no longer affects only Mexico but also its 
neighbours further South, the expansion of methampheta-
mine trafficking from the region to Asia, Europe and 
Oceania, and more recently, the advent of fentanyl manu-
facture have significantly changed the synthetic drug 
landscape and the challenges it poses for countries in the 
region and beyond (see chapter Methamphetamine).
Contrary to the situation in 2014, Latin America and the 
Caribbean is no longer a region characterized by the pres-
ence of low quality “ecstasy”. The significant expansion of 
MDMA (3,4-methylenedioxymethamphetamine) manu-
facture in Europe, which has led to ever higher doses of 
MDMA in “ecstasy” pills and the introduction of new 
forms of presentation such as crystalline MDMA, has 
reached Latin America and the Caribbean, too. While, 
from the perspective of users, it may have led to a more 
predictable content of pills sold as “ecstasy”, the high 
doses of MDMA have also led to overdose events. A 
 growing number of clandestine “ecstasy” laboratories and 
the recent first-ever detection of clandestine MDMA 
 synthesis laboratories further complicate the scenario 
(see chapter Ecstasy). 
While in 2014, the first signs of emergence of NPS were 
already visible, NPS have now become a more common 
feature in many countries in the region. The patterns of 
NPS emergence reflect, as in other regions, the regional 
consumption preferences which, in Latin America and 
the Caribbean, results in a comparatively high proportion 
of NPS with hallucinogenic effects. Some types of NPS, 
for example synthetic cannabinoids, are offered and con-
sumed as such, following similar trafficking patterns as in 
other regions, i.e., direct purchase from online market-
places. However, NPS are also sold under the name of 
other drugs such as “pink cocaine” or “2C-B“ (2,5-dimeth-
oxy-4-bromophenethylamine) and are sometimes still 
found in “ecstasy” products, unknown to users. A 
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particular health risk for users in the region lies in the 
emergence of highly toxic NPS with hallucinogenic 
effects which may have serious negative health implica-
tions and potentially lead to a fatal overdose (see chapter 
Hallucinogens and dissociatives). 
Several countries in the region have since reacted to the 
emergence of NPS with measures including the establish-
ment of national early warning systems, the introduction 
of NPS in national drug control legislation, specific stud-
ies targeting the composition of synthetic drugs, upgrad-
ing of forensic analysis capabilities and the adaptation of 
national drug strategies to address synthetic drugs and 
NPS. Still, many knowledge gaps remain as the impact of 
these measures slowly begins to show results. 
Gender and age dimensions 
In general, gender difference in the use of synthetic drugs 
and NPS follows the pattern known from other, more 
common drugs such as cocaine and cannabis, with male 
prevalence rates of use being significantly higher than 
female rates. These patterns are well reflected for example 
in the annual prevalence rate of “ecstasy” use of the gen-
eral and school populations and in the lifetime prevalence 
of use of LSD (lysergide) and synthetic cannabinoids in 
selected countries in the region. However, the gender gap 
in synthetic drug use seems to narrow in the school and 
university populations in some countries and particularly 
in the non-medical use of prescription medicines and opi-
oids across the region. Recent data show that females in 
some countries are now using certain drugs either at the 
same, or at higher rates, than males. This is best evidenced 
in the case of tranquilizers where prevalence of use is 
higher among women than men in almost every country 
where data are available, a pattern that holds true not only 
in the general population but also in secondary school 
and university populations.3 Gender and age group differ-
ences in prevalence of drug use for synthetic drugs and 
NPS discussed in this report are reflected in much more 
detail in the Organization of American States/Inter-
American Drug Abuse Control Commission’s Report on 
Drug Use in the Americas than what could be done in the 
context of this report. 
Much fewer data are available on gender differences in 
drug-related offences and trafficking of synthetic drugs 
and NPS. In total, only four countries have reported to 
UNODC 172 drug-related arrests of Latin American and 
Caribbean nationals (not specifying sex)  in the most 
3 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
recent time period available from 2016 to 2018.4 
Nevertheless, qualitative research shows that women take 
on diverse roles in drug trafficking organizations in Latin 
America and the Caribbean as well as in other regions5 
and the unequal impact of drug control policy on women 
and men has been highlighted by researchers. Not enough 
information is available to understand to what extent 
these insights also apply for the trafficking of synthetic 
drugs and NPS. Apart from methamphetamine and fenta-
nyl, trafficking of synthetic drugs and NPS may follow 
patterns that are different from those of cocaine and can-
nabis, for example, ordering via the Internet and darknet 
and using mail and parcel services for delivery. Which role 
women play in the trafficking and distribution of syn-
thetic drugs and NPS is currently not well known. It is not 
inconceivable that women from the region trafficking 
cocaine towards Europe might take synthetic drugs back 
home, as typically drug control efforts are geared towards 
preventing outbound trafficking of cocaine rather than on 
incoming synthetic drugs and NPS. Women may also play 
a role in precursor trafficking.6 It remains to be seen if the 
travel restrictions during the coronavirus disease 2019 
(COVID-19) pandemic in 2020 and 2021 will have a last-
ing impact on this trafficking modality.  
Impact of the COVID-19 pandemic
The onset of COVID-19 in Latin America and the 
Caribbean has led Governments to take unprecedented 
measures to contain the spread of the pandemic. In the 
past, synthetic drugs were often trafficked by persons who 
concealed them on their bodies or in luggage. The contain-
ment measures, which have drastically restricted inter-
national travel and in-country mobility, may have 
permanently reshaped this pattern and increased the 
importance of trafficking by postal or courier services. 
Restrictions on inter national travel have led to a sharp 
decline in the number of inter national passengers arriving 
in the region, and movement restrictions within countries 
have hindered street-level dealing in the streets or clubs, 
whereas Internet orders (online drug trafficking) delivered 
by mail or courier services continue to be available during 
4 UNODC, responses to the annual report questionnaire. Argentina, 
Chile, Colombia and Dominican Republic have reported data from 
2016 to 2018. No drug-related arrests were reported by countries in the 
region for the years 2015 and 2019.
5 UNODC, World Drug Report 2018 (United Nations publication, Sales 
No. E.18.XI.9) and Farfán-Méndez, C., “Women’s Involvement in 
Organised Crime and Drug Trafficking: A Comparative Analysis of the 
Sinaloa and Yamaguchi-gumi Organisations”, in The Impact of Global 
Drug Policy on Women: Shifting the Needle, B. Julia, M. Giavana and B. 
Lona, eds. (Bingley, Emerald Publishing Limited, 2020).
6 Giacomello, C. “Women and Drug Policies in Latin America: A Critical 
Review of the United Nations Resolution Mainstreaming a Gender 
Perspective in Drug-Related Policies and Programmes”, Howard Journal 
of Crime and Justice, vol. 56, pp.288-308 (September 2017).
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the pandemic. Online trafficking business models popular 
in the region include illicit drug markets operating in the 
open or dark web, or traffickers exploiting social media ser-
vices as a means to coordinate transactions with users. 
Online trafficking and distribution of drugs via postal or 
courier services in the region are likely to have gained 
popularity during the pandemic. This underlines the risk 
that traffickers may shift even more towards online drug 
trafficking business models to expand their businesses 
and networks, and that this particular trafficking model 
may become a more prominent fixture in the illicit 
regional drug market after the pandemic, not only for syn-
thetic drugs and NPS. In addition, while there is increas-
ing awareness of synthetic drugs amongst Governments 
in the region, many still lack the functional capacity to 
systematically scrutinize their mail stream for such 
substances.7
7 Between June and September 2020, UNODC held three informal 
expert consultations with representatives of national drug observatories 
in Latin America and the Caribbean, the results of which were taken into 
account to describe the impact of the COVID-19 pandemic in this 
report. UNODC, Global SMART Newsletter for Latin America and the 




1 .  OPTIONS FOR RESPONSE IN LATIN AMERICA 
AND THE CARIBBEAN
While the challenges brought about by an expanding and 
diversifying synthetic drugs and NPS market have clearly 
increased in recent years, there is a range of options for 
response available to Governments. 
Information on the use of synthetic drugs and NPS from 
representative, population-based surveys is rudimentary, 
which limits the understanding of age and gender-specific 
differences in their use and associated health risks. This 
limitation is partly due to the fact that the use of synthetic 
drugs and NPS may be more prominent in specific sub-
population groups and that users are not always in a posi-
tion to determine the exact nature of the synthetic 
substances consumed. Thus, several countries have intro-
duced additional information gathering tools, such as 
pooled-urine analysis at electronic music festivals, waste-
water analysis, or information gathered in the context of 
event-based drug checking services. A combination of 
different information gathering tools in a comprehensive 
strategy can provide valuable additional evidence on drug 
use and its harm to inform drug policy responses. 
No other region apart from Europe has such a network of 
national early warning systems on drugs as Latin America 
and the Caribbean, linked through the regional early 
warning system of the Americas hosted by the OAS/
CICAD. Argentina, Chile, Colombia, Trinidad and 
Tobago and Uruguay have spearheaded this development. 
Other countries are following at various stages of devel-
opment, with support from the existing national early 
warning systems, OAS/CICAD and UNODC. With its 
horizontal and vertical links, this network could be fur-
ther strengthened. 
The concentration of drug policy and particularly law 
enforcement efforts on the main problem drug in the 
region, cocaine, dubbed “cocainization” by some, is still 
noticeable. However, recent national drug strategy docu-
ments8 have recognized the synthetic drug dimension of 
the drug problem and the “de-cocainization” in the sense 
8 For example, in El Salvador, see El Salvador, Comisión Nacional 
Antidrogas, El Salvador Informe Nacional 2020 sobre la Situación de las 
Drogas (December 2020).
of a broadening of the focus of national drug policy may 
already be on the way. Part of this reorientation could be 
to pay more attention to in-bound trafficking via inter-
national mail and parcel services, for example, by applying 
mail profiling techniques and also, in a post-COVID-19 
situation, air passenger profiling using modern field 
 testing technologies for the rapid identification of 
 synthetic drugs and NPS at the border. 
One of the lesser known achievements of countries in 
Latin America and the Caribbean is the introduction of 
NPS legislation by some countries covering a much wider 
range of substances than those brought under inter-
national control as well as innovative legal approaches 
such as generic definitions of NPS in drug laws.9 Still, 
many gaps remain, and many countries may not have been 
able to keep pace with the rapid emergence of NPS and 
the need to give Governments the necessary legal 
 instruments to control them, thus creating a dangerously 
uneven regional legal landscape for these substances and 
their precursors. Here, coordinated efforts could go a long 
way towards harmonizing the control status of NPS in the 
region, and foster intraregional collaboration. 
A similarly uneven landscape exists in terms of forensic 
capacity to identify synthetic drugs and NPS. This may be 
due to lack of suitable analytical instruments, methodolo-
gies and know-how but might also sometimes be the 
result of a very limited analytical focus of laboratories on 
cocaine, heroin and cannabis. In such cases, a strategic 
re-orientation could lead to a better understanding of the 
real synthetic drug situation in a country, while capacity- 
building, investment in instruments and human resources, 
and ensuring stable funding for forensic work will be 
 necessary in others. 
Finally, countries may consider paying more attention to 
illicit, drug-related activities on online marketplaces 
(cybercrime) including in the darknet. 
9 For more information please see the UNODC, Early Warning Advisory 




The use of stimulants has a stimulatory effect on the cen-
tral nervous system and influences the levels and action of 
the important neurotransmitters: dopamine, norepine-
phrine and serotonin. The differing degrees to which a 
substance affects these neurotransmitters contributes to 
the psychostimulant properties of individual stimulants. 
Synthetic stimulants discussed in this report include 
“ecstasy”, amphetamine and methamphetamine, collec-
tively known as amphetamine-type stimulants (ATS), as 
well as a structurally diverse group of NPS with stimulant 
effects.10
”Ecstasy”
Over the last few years, data relating to the annual preva-
lence of “ecstasy” use among the general population point 
10 UNODC, Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
to an increase in “ecstasy” use and a higher prevalence rate 
among the males compared to females in most countries. 
For instance, Uruguay showed the highest increase of the 
annual prevalence rate of “ecstasy” use among the general 
population in the region, with an increase from 0.4 per 
cent in 2014 to 0.9 per cent in 2018. The annual preva-
lence rate among males in Uruguay increased from 0.7 per 
cent in 2014 to 1.1 per cent in 2018 and from 0.1 per cent 
to 0.6 per cent for females, respectively. Also, in Argentina, 
Chile and Costa Rica, an increase in the annual preva-
lence of “ecstasy” use among the general population can 
be observed. In all countries of the region with recent 
data, males showed higher prevalence rates than women, 
except for Bolivia (Plurinational State of), where, how-
ever, prevalence rates were very low and gender difference 
should be interpreted with caution.11
11 UNODC, responses to the annual report questionnaire.
Figure 1 .  Annual prevalence of “ecstasy” use rates among the general population, in selected 
Latin American and Caribbean countries, by sex and total, 2010–2018
Source: UNODC, responses to the annual report questionnaire .
Note: The graph represents the latest period available (2011-2018) disaggregated by sex . The general population in Argentina, Chile, 
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Drug use surveys conducted among students in several 
Latin American and Caribbean countries also provide 
further insight into “ecstasy” use. In 2016 and 2017, drug 
use surveys conducted among secondary school students 
found an annual prevalence of “ecstasy” use of 1.4 per cent 
in Colombia, 1.3 per cent in Uruguay,12 1.23 per cent in 
Ecuador,13 1.2 per cent in Honduras, and 1.08 per cent in 
Chile.14 
Figure 2 .  Annual prevalence of “ecstasy” use 
rates among the school population, 
in selected Latin American and 
Caribbean countries, 2016–2017
Source: UNODC, responses to the annual report questionnaire 
and other government sources .
Note: The graph represents the latest period available 
(2016/2017) . The school population in Ecuador and Uruguay 
refers to population aged 12/13-17 and in Chile, Colombia and 
Honduras the category refers to 15–16-year-old school 
students . 
Drug use surveys conducted among university students 
show an annual prevalence of “ecstasy” use at 2.0 per cent 
in Colombia in 2016, which is higher than the 0.75 per 
cent of “ecstasy” use among the same population group in 
2012. In Bolivia (Plurinational State of), the annual prev-
alence of “ecstasy” use at 0.24 per cent among university 
students in 2016 was also somewhat higher than the 0.01 
per cent reported in 2012. However, in Peru, the annual 
prevalence of “ecstasy” use stood at 0.06 per cent in 2016, 
signifying a lower figure than the 0.28 per cent reported in 
2012.15
12 UNODC, responses to the annual report questionnaire. Annual 
prevalence data in Colombia refer to aged group 15–16 (year of estimate 
2016) and in Uruguay to aged group 13–17 (year of estimate 2016).
13 Encuesta sobre uso y consumo de drogas ilícitas en estudiantes de 9no. 
EGB, 1ero. y 3ero. de bachillerato, 2016 (year of estimate 2016 and age 
group 12-17).
14 UNODC, responses to the annual report questionnaire. Annual 
prevalence data refer to aged group 15–16 in Honduras (year of estimate 
2016) and Chile (year of estimate 2017). 
15 UNODC, responses to the annual report questionnaire, OAS/CICAD 
and other government sources. 
Figure 3 .  Annual prevalence of “ecstasy” use 
rates among university students, in 
selected Latin American and 
 Caribbean countries, 2012 and 2016 
Source: UNODC, responses to the annual report questionnaire, 
OAS/CICAD and government reports . 
Recently, the Government of Trinidad and Tobago has 
expressed concern about perceived increases in the use of 
MDMA and other synthetic drugs, particularly among 
youths. As a result, the Government amended the national 
Dangerous Drugs Act to include MDMA and LSD, as well 
as several NPS and ketamine, in December 2019.16 
However, recent data on the prevalence of “ecstasy” use 
from population-based surveys are not available for the 
country.
Generally, prevalence serves as an indicator in determining 
the degree of use. The available prevalence of use data sug-
gest some increase in the use of “ecstasy” in certain coun-
tries in Latin America and the Caribbean among the 
general population. However, as “ecstasy” is typically more 
popular among specific population groups and its con-
sumption is often linked to specific events, for example, 
electronic music festivals or visiting clubs, the value of esti-
mates from drug use surveys among the general popula-
tion is limited. Although other drugs, particularly cannabis 
and cocaine, continue to have higher prevalence-of-use 
rates compared to “ecstasy”, the latter has become a grow-
ing concern because of the use rates among the high school 
and undergraduate student populations.17 A caveat is that 
the prevalence of use data for many countries is dated. 
Moreover, the significant health risks entailed in the use of 
“ecstasy” and increases of health risk associated with the 
emergence of “ecstasy” in new forms of presentation are 
not necessarily captured in prevalence of use surveys. 
16 Trinidad and Tobago,  Act No. 24 of 2019 , Legal Supplement Part A to 
the  Trinidad and Tobago Gazette , vol. 58, No. 183 (December 2019). 
17 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 



































































An emergence of crystalline 
“ecstasy” and high dose tablets
As in other parts of the world, the health risks associated 
with the use of “ecstasy” in Latin American and Caribbean 
countries have risen significantly and are being monitored 
by early warning systems in the region. Particularly in the 
last few years, Latin American and Caribbean countries 
have reported the emergence of high-dose “ecstasy” prod-
ucts including crystalline “ecstasy” and tablets with a high 
MDMA content on drug markets. In July 2018, Uruguay 
issued a public alert via the national early warning system 
on the severe adverse health consequences of high- 
potency MDMA in crystalline and powder form.18 
According to the alert, MDMA accounted for more than 
60 per cent of the content of samples drawn from the 
33.5  kg of powder or crystalline “ecstasy” seizures 
 analysed by the Forensic Technical Institute in 2018. In 
the same year, 12 out of 20 samples of seized “ecstasy” 
 tablets tested by the Forensic Technical Institute 
 contained more than 150 mg of MDMA in each tablet.19 
In December 2019, the early warning system in Colombia 
also published an alert on the health risks  associated with 
the use of “ecstasy” tablets with high MDMA content.20 In 
Chile, the availability of crystalline ecstasy has also been 
observed on local drug markets.21
In Colombia, the use of crystalline “ecstasy” and high-
dose tablets have also featured in recent drug use studies. 
In 2019, the results of the Global Drug Survey in 
Colombia showed that while 81 per cent of “ecstasy” 
users reported to have consumed the substance in tablet 
form, 47 per cent had consumed “ecstasy” in crystalline 
form and 17 per cent in the form of capsule.22 A study con-
ducted at electronic music festivals in Colombia during 
the second half of 2018 also revealed that 60 per cent of 
the ecstasy tablets submitted to drug testing services for 
analysis had a high content of MDMA.23
18 Uruguay, Observatorio Uruguayo de Drogas, Sistema de Alerta 
Temprana, Presencia de MDMA (éxtasis) en forma de cristales y polvos en 
Uruguay – Agosto 2018, press release, 31 August 2018.
19 Perna, M., Mariño J., and Bonda, J., Cuantificación de MDMA en 
muestras incautadas: validación y situación actual en Uruguay, poster 
prepared for the regional TIAFT conference Latin America, 26-28 
November 2018.
20 Colombia, Observatorio de Drogas de Colombia, Alerta sobre alto 
contenido de MDMA en muestras de comprimidos de éxtasis, alert, 
27 July 2019.
21 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del narcotráfico 
– Informe 2020 (May 2020) and Acción Técnica Social, Encuesta mundial 
de drogas 2019. El mundo atento de Sur América (November 2019).
22 Acción Técnica Social, Encuesta mundial de drogas 2019. El mundo 
atento de Sur América (November 2019).
23 Échele Cabeza, Informe segundo semestre de 2018 (February 2018). 
The “ecstasy” market remains diversified
Whereas some “ecstasy” products have a very high con-
tent in MDMA, other products continue to be available 
on the illicit market that are sold as “ecstasy” but contain 
little or no MDMA. For instance, in Colombia, products 
sold as “crystalline MDMA” in 2018 have been found to 
contain methamphetamine and synthetic cathinones, 
instead of MDMA,24 and a growing number of severe 
intoxications was noticed caused by the use of products 
sold as MDMA that were found to contain large amounts 
of methamphetamine.25 In January 2017, the Colombian 
early warning system issued an alert on the detection of 
synthetic cathinones, such as methylone, ethylone and 
alpha-PVP (alpha-pyrrolidinovalerophenone),26 in tablets 
sold as “ecstasy” and in capsules and powders sold as 
 supposedly “pure” MDMA.27 
In Uruguay, in 2018, “ecstasy” tablets with varying 
MDMA content involving substances such as caffeine, 
amphetamine, ephedrine, MDA (3,4-methylenedioxy -
amphetamine), N-ethyl-MDA (3,4-methylenedioxy-N- 
ethylamphetamine) were detected, but also some with a 
high MDMA dose28 as well as MDMA in crystalline 
form.29 While some studies stated that MDMA was found 
in some samples seized as “ecstasy” in Sao Paolo, Brazil, 
MDMA was not found in selected “ecstasy” samples in 
2016 which instead contained a combination of other 
substances such as caffeine, dextromethorphan, a 
 methylone analogue and clobenzorex.30,31 
In Chile, the Analysis Section of the Institute of Public 
Health assessed the quantity, composition and purity of 
drugs seized between March and June 2020 and  compared 
the results with those derived over the same period in 
2019 to determine the potential impact of the Covid-19 
pandemic on the drug market. As part of this study, 480 
24 Ibid.
25 Échele Cabeza, Intoxicaciones graves por consumo de pastillas con 
metanfetaminas, alert, 22 March 2018. 
26 Methylone, ethylone and alpha-PVP have been placed under inter-
national control in recent years.
27 Colombia, Observatorio de Drogas de Colombia, Aparición de nuevas 
sustancias psicoactivas en Colombia (Bogotá, 2017). 
28 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, Drug 
adulterants and their effect on the health of users. A critical review 
(Washington D.C., 2019). 
29 Uruguay, Observatorio Uruguayo de Drogas, Sistema de Alerta 
Temprana, Presencia de MDMA (éxtasis) en forma de cristales y polvos en 
Uruguay – Agosto 2018, press release, 31 August 2018. 
30 Clobenzorex is an anorectic drug with stimulant properties not under 
inter national control. 
31 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, Drug 
adulterants and their effect on the health of users. A critical review 
(Washington D.C., 2019).
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“ecstasy” samples were analysed in 2019 and 348 samples 
in 2020 in addition to a range of other drugs. In this study, 
tramadol32 was found in 7 times the number of “ecstasy” 
samples in 2020 than in 2019. Furthermore, sertraline33 
was found in twice as many “ecstasy” samples in 2020 
than in 2019.34
On the whole, “ecstasy” products in Latin America and 
the Caribbean are diverse in terms of their form of pres-
entation and highly variable in terms of MDMA content, 
which may or may not be substituted by other stimulants. 
This situation exacerbates the health risks “ecstasy” users 
are exposed to. 
The perceived availability and access to “ecstasy” products 
appears to be comparatively high in some countries in the 
region. For instance, studies conducted among university 
students showed that the perceived ease of access35 to 
“ecstasy” was highest at among 20.4 per cent of university 
students in Colombia in 2016, as opposed to other coun-
tries including Bolivia (Plurinational State of), Ecuador, 
El Salvador, Panama, Peru and Uruguay where 5 to 10 per 
cent of university students perceived an ease of access to 
“ecstasy” that year.36 
Annual amounts of “ecstasy” 
seizures fluctuate
Between 2015 and 2019, “ecstasy” seizures in Latin 
America and the Caribbean have fluctuated, with the 
lowest total annual quantity of around 240 kg reported in 
2018 and the largest quantity of about 640 kg reported in 
2019. Over the same five-year period, the largest total 
quantity of 725 kg of “ecstasy” seized in the region was 
reported by Brazil, followed by Argentina at 390 kg, and 
Chile at 380 kg. These three countries accounted for 
about 80 per cent of “ecstasy” seized in the region during 
this five-year period. 
32 Tramadol is a pharmaceutical opioid not under inter national control.
33 Sertraline is a selective serotonin reuptake inhibitor used to treat 
depression, and sometimes panic attacks, obsessive compulsive disorder 
and post-traumatic stress disorder. For more information please see 
NHS, Sertraline (December 2018). Available at NHS, Sertraline, 12 
December 2018. Available at www.nhs.uk/medicines/sertraline/
34 Instituto de Salud Pública de Chile, ISP detecta variaciones en la presencia de 
adulterantes en decomisos de cocaína y otras drogas (July 2020).
35 According to OAS/CICAD, the definition of the perception of ease of 
access is a subjective indicator that has to do with how easy or difficult it 
is for someone to obtain a particular drug, whether by purchasing it or 
obtaining it from friends or acquaintances. A drug perceived as easy to 
obtain is generally cheaper and more available on the market (see 
Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019)).
36 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
Figure 4 .  “Ecstasy” seizures reported in 
Latin America and the Caribbean, 
 2015–2019
Source: UNODC, responses to the annual report questionnaire . 
Note: Seventeen reporter countries included .
Possible intensification of 
“ecstasy” trafficking
Although the annual quantities of “ecstasy” seizures 
reported for Latin America and the Caribbean have fluc-
tuated with no clear overall trend, certain countries, such 
as Chile, Costa Rica and Panama, have nevertheless 
reported an increase in “ecstasy” seizures. Possible rea-
sons for the strong year-on-year fluctuations might be due 
to the modus operandi of traffickers, with “ecstasy” typi-
cally being sent via mail and parcel services or trafficked 
by air passengers in small amounts, when compared to 
cocaine or cannabis seizures. Thus, larger, individual ship-
ments of “ecstasy” seized have a strong influence of 
national aggregate figures. 
In Chile, for example, MDMA accounted for more than 
74 per cent of all seized synthetic drugs in 2019, and the 
amounts of seized single doses by Chilean Police increased 
significantly from 203 in 2013 to more than 1.2 million in 
2019.37 Chile has reported several large individual sei-
zures over the years, for instance in November 2019, a 
national record quantity of approximately 126,000 
“ecstasy” tablets close to the border with Bolivia 
(Plurinational State of) in a shipment en route to the 
 capital region.38 In 2018, authorities in Chile  disseminated 
an alert on the extensive presence of “ecstasy” in the 
national drug market. The Observatory of Drug 
Trafficking in Chile observed that between March 2016 
and March 2017, “ecstasy” or MDMA seizures in the 
37 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del narcotráfico 
– Informe 2020 (May 2020). 
38 Chile, Fiscalía de Chile, Fiscalía Tarapacá y Brianco Iquique logran la 




























country exceeded those of any other synthetic drug, with 
seizures in tablet form accounting for more than 80 per 
cent of all synthetic drugs seized in the country.39
In the Caribbean, reported “ecstasy” seizures are low and 
sporadic. In Barbados, for the first time since 2012, the 
Royal Barbados Police Force reported to have seized 
2,000 “ecstasy” pills in 2017 and again 20 g in 2018.40 
During the first nine months of 2019, Antigua and 
Barbuda also reported to have seized 37 tablets of 
MDMA.41 Although Trinidad and Tobago have annually 
reported low quantities of synthetic drug seizures over 
the last few years, authorities reported the seizure of over 
5,000 synthetic drug tablets in early 2019. Most of the 
tablets were found to contain MDMA in combination 
with other substances such as amphetamine, metham-
phetamine and ketamine.42 The Dominican Republic 
reported annual amounts of “ecstasy” seized below 1 kg in 
2016, 2017 and 2018 but reported 13 kg in 2019.43 
Several countries in Latin America and the Caribbean 
indicate European countries to be the origin of “ecstasy” 
trafficked into the region in recent years with Belgium, 
Germany and the Netherlands being frequently men-
tioned.44 “Ecstasy” is predominantly trafficked from 
Europe to Latin America and the Caribbean via postal 
services and, in pre-COVID-19 times, also by air passen-
gers. For example, in 2018, a total of 328 kg of MDMA 
were reported to have been seized at European postal cen-
tres of which most is suspected to have been destined for 
onward trafficking to Latin America and to a lesser extent, 
other regions.45 
39 OAS/CICAD, “Data from the early warning system for the Americas”, 
Information Bulletin, vol. 1 (April 2020). Available at www.cicad.oas.org/
oid/pubs/Bolet%C3%ADn%20ENG.pdf
40 Jonathan Yearwood and Laura Lee Foster, The Barbados Drug 
Information Network: Findings from the 2017 & 2018 Reports, 
presentation, 15 July 2020.
41 United States, Department of State, International Narcotics Control 
Strategy Report 2020 Vol. I: Drug and chemical control (March 2020).
42 UNODC, “Trinidad and Tobago: Minister of National Security alerts 
public on health risks of synthetic drugs”, Early Warning Advisory 
Newsclip, April 2019. Available at www.unodc.org/LSS/Announcement/
Details/b697596e-81b8-4370-8e13-b601343c59ff
43 UNODC, responses to the annual report questionnaire and Chile, 
Fiscalía de Chile, Fiscalía y Brianco desarticulan banda criminal que 
fabricaba pastillas de  éxtasis  en Santiago, press release, 16 May 2020.
44 UNODC, responses to the annual report questionnaire. Recent years 
refers to the time period 2014 to 2019.
45 European Monitoring Centre for Drugs and Drug Addiction and 
Europol, EU Drug Markets Report 2019 (Luxembourg, Publications 
Office of the European Union, 2019).
An expansion of “ecstasy” 
laboratories: from cutting and 
re-tableting to manufacture
Several countries in Latin America and the Caribbean, 
such as Argentina, Brazil, Chile, Colombia and the 
Dominican Republic, have dismantled “ecstasy” laborato-
ries in recent years, which were mainly used for cutting 
and tableting operations. Argentina reported the disman-
tling of eight “ecstasy” laboratories in 2019, a much higher 
number than in the previous five years.46 
In Brazil, the growing popularity of “ecstasy” may have 
attracted organized crime groups in the region to produce 
the drug locally and go beyond re-tableting of higher dose 
ecstasy pills or crystalline MDMA from Europe into lower 
dose pills for the local market. At least eight MDA and/or 
MDMA47 manufacturing laboratories were reported to 
have been dismantled between 2018 and 2020. Previously, 
the laboratories reported to have been dismantled in the 
country were typically used for the purpose of cutting and 
re-tableting “ecstasy” trafficked from other countries, 
whereas more recently laboratories discovered in the 
 southern parts of Brazil involved the entire production 
chain, including synthesis.48 For instance, when a  laboratory 
was discovered by authorities in Brazil in July 2019, a 
number of chemicals and utensils used for the manufacture 
of MDMA were also found on the site, in addition to other 
substances such as methamphetamine and NBOH 
 compounds also suspected to have been manufactured at 
this laboratory. At another laboratory reported to have 
been dismantled in Brazil in February 2019, a total of 39 kg 
of chemicals and drugs were seized, including 9 kg of MDA 
in powder form.49 Most recently, in July 2020, a total of 
18 kg of pure MDMA and precursors were reported to have 
been seized in Curitiba, Brazil. The use of the same 
 synthetic conversion route to obtain the active ingredient 
was used in most of the dismantled clandestine  laboratories. 
The information released on these cases suggests that the 
criminal organizations involved used the services of an 
experienced chemist as opposed to mere “cooks”.50 
Furthermore, the Brazilian Federal Police suspected already 
in 2018 that the large amounts of MDA reported to have 
46 UNODC, responses to the annual report questionnaire.
47 MDA and MDMA are “ecstasy”-group substances often found in 
ecstasy  products.
48 UNODC, “Brazil: Emergence of ‘ecstasy’ manufacture in clandestine 
laboratories”, Early Warning Advisory Newsclip, August 2020. Available at 
www.unodc.org/LSS/Announcement/Details/e7c21143-eb4d- 47e6- 
9a70-723eb6e47c29
49 Official communication on July 2020 with the Federal Police in Brazil 
- SEDQ/DIREN/CGPRE/DICOR/PF.
50 UNODC, “Brazil: Emergence of ‘ecstasy’ manufacture in clandestine 
laboratories”, Early Warning Advisory Newsclip, August 2020. Available at 
www.unodc.org/LSS/Announcement/Details/e7c21143-eb4d-47e6- 
9a70-723eb6e47c29
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been seized in the country in 2017 might have been con-
nected to local MDA manufacture.51
In Chile, before 2014, only “ecstasy” in tablet form was 
seized, but from 2014 onwards, “ecstasy” was also seized 
in wholesale amounts in powder or crystalline form. 
While “ecstasy”, i.e., MDMA in crystalline or powder 
form, can and is being consumed as such in South 
America, the main form of presentation at the retail level 
continues to be in tablet form. Larger amounts seized at 
the border can therefore point to the existence of tablet-
ing facilities in destination countries. Indeed, in 2019 and 
2020, several tableting manufacturing facilities that pro-
cess tablets from high-purity MDMA were dismantled in 
Chile.52 For example, in May 2020, Chilean authorities 
dismantled a criminal organization dedicated mainly to 
the manufacture and marketing of “ecstasy” pills which 
operated a pill-pressing facility in Santiago de Chile to 
produce MDMA tablets.53
51 Servico Público Federal, Polícia Federal, Instituto Nacional de 
Criminalística, Synthetic drugs 2018 report (2018). 
52 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del narcotráfico 
– Informe 2020 (May 2020).
53 Chile, Fiscalía de Chile, Fiscalía y Brianco desarticulan banda criminal que 
fabricaba pastillas de  éxtasis  en Santiago, press release, 16 May 2020.
In the Dominican Republic, authorities also reported the 
dismantling of a laboratory manufacturing “ecstasy” and 
ketamine in 2017.54
Is illicit manufacture of “ecstasy” 
emerging in the region?
“Ecstasy” synthesis in the region is a fairly new develop-
ment and has to date only been reported from Brazil where 
at least eight clandestine MDA and/or MDMA manufac-
turing laboratories were dismantled between 2018–2020.55 
One chemical precursor frequently found in clandestine 
“ecstasy” laboratories in Brazil over the last two years was 
helional. Helional is not under inter national control and is 
used in licit industry as a perfume in soap and laundry 
detergent. Reports of its use in clandestine laboratories for 
the illicit manufacture of “ecstasy”-group substances other 
than those discovered in Brazil have so far been limited to 
Canada and the Netherlands.56,57 
54 International Narcotics Control Board, Report of the International 
Narcotics Control Board for 2018 (United Nations publication, Sales No. 
E.19.XI.2).
55 UNODC, Brazil: Emergence of  ecstasy  manufacture in clandestine 
laboratories Early Warning Advisory Newsclip, August 2020. Available at 
www.unodc.org/LSS/Announcement/Details/e7c21143-eb4d-47e6- 
9a70-723eb6e47c29
56 Official communication on July 2020 with Federal Police in Brazil - 
SEDQ/DIREN/CGPRE/DICOR/PF.
57 International Narcotics Control Board, Precursors and chemicals 
frequently used in the illicit manufacture of narcotic drugs and psychotropic 
substances 2018 (United Nations publication, Sales No. E.19. XI.6).
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Schedule II, 1971 Convention
Not under international control
Source: UNODC elaboration .
132. StImuLAntS
Amphetamine
Estimating the use of amphetamine, prescription stimu-
lants and methamphetamine in a region with evidence of 
large-scale illicit manufacture of amphetamine and meth-
amphetamine should be of high interest. Indeed, over the 
last few years, some countries in Latin America and the 
Caribbean have reported on the prevalence of ampheta-
mine use. For instance, drug use studies among the 
 general population revealed a lifetime prevalence of 
amphetamine use at 0.02 per cent in Costa Rica in 2015 
and 1.2 per cent in Chile in 2016. The lifetime prevalence 
of amphetamine use among secondary school students 
was found to be 0.2 per cent in Uruguay in 2014 and 
4.4  per cent in Chile in 2015, and among university 
 students 1.1 per cent in Colombia and 0.1 per cent in Peru 
in 2016.58
Challenges for estimating amphetamine 
and methamphetamine use
However, there are variations in the definition of  “amphet-
amine” use among drug use surveys in Latin America and 
the Caribbean, which limit cross-country comparison 
and trend analysis. The general caveat of drug use preva-
lence data for many countries being dated while the syn-
thetic drugs market is very dynamic is an additional 
serious limitation. Prevalence studies in the region some-
times include “amphetamines” in their list of substances 
for drug use analysis, which, in addition to amphetamine, 
can also include other ATS such as methamphetamine 
and/or prescription stimulants. Moreover, amphetamine 
is being sold in the region in combination with other sub-
stances under various names so that drug users might be 
consuming amphetamine without their knowledge.
Recent quantities of seizures are low 
Annual amphetamine seizures reported by countries in 
Latin America and the Caribbean in the period 2015–
2019 have remained below 0.2 tons with the exception of 
Mexico in 2015 and Guatemala, which reported multi-ton 
seizures of amphetamine in 2015, 2016 and 2019. It 
remains unclear whether these seizures of amphetamine 
were intended for local consumption and/or onward 
trafficking.
58 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
Table 1 .  Amphetamine seizures reported in 
Latin American and Caribbean 
 countries, 2015–2019 (in kilograms)
COuntrY 2015 2016 2017 2018 2019
Argentina 7.1 0.4 32.9 0.6 1.4
Brazil 179.6 4.0 43.6  12.7
Chile 0.05 0.3 0.04 0.2 0.04
dominican 
republic
  3.1   
Ecuador   0.4 7.6 1.8
El Salvador     0.1
Guatemala 12,700.8  22.7 1.1 16,877.5
mexico 300.6 1.1 1.3 3.3 2.5
Panama  0.2 0.02   




 0.01 4.8 15.9 0.8
total 13,188.3 6.0 108.8 56.3 16,896.8
Source: UNODC, responses to the annual report questionnaire .
A particularly large shipment of 317 kg of amphetamine 
was seized in the importation area of La Aurora 
International Airport in Guatemala City in January 
2019.59 The reasons for the stark fluctuations in annual 
seizure amounts and large single shipments of ampheta-
mine in Guatemala remain unclear. Based on the informa-
tion on amphetamine use, the amounts seem too large to 
be destined for the local drug market.
Comparatively large annual seizure amounts have also 
been reported by Brazil in some years. In Brazil, ampheta-
mine in combination with other substances is also sold 
under street drug names such as “Nobesio”, “Nobesio 
Extra Forte”, “Bolinha” and “Rebite”.60 In June 2019, Brazil 
reported the seizure of 37,500 tablets of “Nobesio”, which 
are believed to have been trafficked from Paraguay.61
59 Guatemala, Dirección General de la Policía, Más de 300 kilogramos de 
Anfetamina, droga sintética, localizados en Aeropuerto Internacional La 
Aurora, press release, 29 January 2019. Available at www.sgaia.gob.gt/
mas-de-300-kilogramos-de-anfetamina-droga-sintetica-localizados-en-
aeropuerto-internacional-la-aurora/
60 According to court documents, these tablets may contain, among 
other substances, clobenzorex, methamphetamine or synthetic 
cathinones. See, for example: Tribunal de Justiça de Minas Gerais, 11 
November 2014 (available at www.conjur.com.br/dl/tj-mg-
medicamento-ilegal-trafico.pdf), Tribunal de Justiça do Amapá, 6 
November 2018 (available at https://tj-ap.jusbrasil.com.br/
jurisprudencia/652079710/apelacao-apl-7935820178030009-ap) and 
Superior Tribunal de Justiça, 17 April 2020 (available at www.jusbrasil.
com.br/diarios/294159839/stj-22-04-2020-pg-8001?ref=serp).  
61 Brazil, Policía Militar de Mato Grosso, PM prende irmãos e apreende em 
Matupá 37 mil cápsulas de “rebite”, press release, 21 June 2019. Available 
at www.pm.mt.gov.br/-/12030836-pm-prende-irmaos-e-apreende-em- 
matupa-37-mil-capsulas-de-rebite-
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Amphetamine continues to be 
manufactured in the region
Over the last few years, Argentina and Guatemala were 
the only countries in the region reporting clandestine 
amphetamine manufacturing facilities. Argentina 
reported an amphetamine laboratory for the first time in 
2019. In Guatemala, 14 amphetamine laboratories were 
dismantled between 2013 and 2019.62
Moreover, amphetamine may be manufactured in other 
parts of Latin America and the Caribbean under different 
brand names. For instance, in April 2020, Brazilian 
authorities dismantled an illicit “Nobesio” laboratory in 
the Tocatins state, and seized machinery, packaging 
equipment and large amounts of chemicals and tablets at 
the site. Authorities suspect that the tablets were intended 
to be trafficked to other cities within Tocantins state such 
as Goias, Mato Grosso and Maranhao. Although there 
have been reports of amphetamine being among the vari-
ety of substances included in tablets sold as “Nobesio”, 
there is not enough information available to confirm the 
presence of amphetamine in tablets manufactured by this 
particular laboratory in Brazil. 63
Methamphetamine
Methamphetamine seizures in Latin America and the 
Caribbean have fluctuated over the years. Annually, by far 
the largest amount of methamphetamine seized in the 
region was reported by Mexico. Between 2015 and 2019, 
large annual seizures ranging between 100 kg and 500 kg 
were also reported by Guatemala, Panama, Brazil and 
Argentina, in descending order of amounts seized.64 In 
2017 and 2018, the Royal Barbados Police Force reported 
the first methamphetamine seizures in the country 
amounting to less than 2 kg.65
62 UNODC, responses to the annual report questionnaire.
63 Brazil, Ministerio Publico Estado do Tocatins, Operação Nobésio 
prende traficantes e desarticula um dos maiores fabricantes de 
metanfetaminas do centro-norte do país, press release, 18 April 2020.
64 UNODC, responses to the annual report questionnaire.
65 Jonathan Yearwood and Laura Lee Foster, The Barbados Drug 
Information Network: Findings from the 2017 & 2018 Reports, 
presentation, 15 July 2020.
Figure 6 .  Methamphetamine seizures reported 
in Latin America and the Caribbean, 
2015–2019
Source: UNODC, responses to the annual report questionnaire . 
Note: Eleven reporting countries included in the category 
“Other countries” .
Concentration or spread of 
methamphetamine laboratories?
Since 2015, the number of methamphetamine laborato-
ries reported within the region has declined from almost 
200 laboratories to just 46 laboratories in 2019. Between 
2015 and 2019, only Argentina (three laboratories), 
Guatemala (four laboratories) and Mexico reported dis-
mantling methamphetamine laboratories within the 
region.66
Figure 7 .  Number of methamphetamine 
laboratories dismantled in Mexico, 
2015–2019
Source: UNODC, responses to the annual report questionnaire .





















































Although the number of laboratories being dismantled in 
Mexico has declined over the years, this does not necessar-
ily indicate a decline in methamphetamine manu facture in 
the country. According to the United States Drug 
Enforcement Administration (DEA), the production 
capacity of individual laboratories in Mexico has recently 
increased, so that a smaller number of large-scale manufac-
turing facilities are required to produce large amounts of 
methamphetamine.67 In Mexico, methamphetamine is pre-
dominantly manufactured in the states of Baja California, 
Sinaloa, Jalisco and Michoacan,68  frequently involving 
manu facturing operations on an industrial-scale. A further 
explanation for the declining clandestine laboratory sei-
zures in Mexico could be the geographic diversification of 
locations to Mexico’s  southern neighbours.69
Increasing methamphetamine trafficking 
towards Canada and the United States
Large amounts of methamphetamine are trafficked from 
Mexico to the United States and an increasing amount of 
methamphetamine has been seized in both countries 
along this part of the border. In 2018, methamphetamine 
seizures along this border were more than three times 
higher than in 2013,70 and the amounts seized in the 
financial year 2020 were double those of 2018, indicating 
a continuing increasing trend.71 Total methamphetamine 
seizures in the United States were at 120 tons in 2019, 
almost double the amount of 2017.72 To impede  detection 
efforts at the border, Mexican traffickers continue to 
 dissolve methamphetamine in solvents (frequently in 
 acetone-based fluids) and traffic it in liquid form across 
the northern border. This “liquid methamphetamine” is 
generally destined for a conversion laboratory in the 
 destination country, where the solution is converted back 
to crystalline methamphetamine.73
Recently, Canada has reported of an influx of metham-
phetamine believed to have originated from Mexico. For 
67 United States Drug Enforcement Administration, Methamphetamine 
Seizures Continue to Climb in the Midwest, press release, 10 July 2019. 
68 Mexico, Fiscalía General de la Republica, Unidad Especializada en 
Investigación de Delitos Contra la Salud ( January 2015).
69 European Monitoring Centre for Drugs and Drug Addiction and 
Europol, Methamphetamine in Europe: EMCDDA-EUROPOL threat 
assessment 2019 (Luxembourg, Publications Office of the European 
Union, 2019). 
70 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
71 United States Customs and Border Protection, Drug Seizure Statistics, 
online database ( January 2021). Available at www.cbp.gov/newsroom/
stats/drug-seizure-statistics
72 UNODC, responses to the annual report questionnaire. 
73 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
instance, in February 2019, the Ontario Provincial Police 
in Canada reported to have seized 180 kg of metham-
phetamine concealed in spare tyres shipped with cars 
from Mexico.74 
Mexican criminal groups expand 
trafficking to Asia and Oceania
In addition to the trafficking of methamphetamine from 
Mexico to the United States and Canada, there are also 
increasing reports of methamphetamine being trafficked 
to various other regions of the world. As some shipments 
originate in the United States, it is not always possible to 
determine whether the methamphetamine was manufac-
tured in Mexico or in other countries but the size of the 
shipments suggest that criminal groups with access to 
large amounts of methamphetamine are involved. 
Particularly Australia, Japan and New Zealand have 
reported large-scale methamphetamine seizures and traf-
ficking operations linked to Mexico in recent years. For 
instance, in Australia, the Australian National Police and 
the Australian Border Force reported seizing 755 kg of 
crystalline methamphetamine concealed in a shipment of 
cow hides from Mexico in August 2019, and a Mexican 
national was arrested in connection with the case.75 In 
2016, the Australian National Police traced a shipment of 
138 kg of methamphetamine that had arrived in Sydney, 
Australia from Mexico. This trafficking incident was 
linked to a West African trafficking network with connec-
tions to the Sinaloa cartel.76 In addition to these large scale 
seizures, there have been a number of other cases involv-
ing methamphetamine being trafficked from Mexico to 
Australia in recent years, by plane, by ship and by mail.77
In Japan, in January 2018, around 250 kg of methamphet-
amine concealed in laser cutting devices delivered from 
Mexico, were seized at the Tokyo seaport78 and in 2017, 
Japanese authorities seized almost 230 kg of metham-
phetamine, concealed in steel pipes from Mexico at the 
74 Canada, The Ontario Provincial Police’s official twitter 
account.  Available at https://twitter.com/OPP_News/status/ 
1100799658895396864
75 Australia, Australian Federal Police, 755kg of methamphetamine 
imported from Mexico in cow hides, press release, 29 August 2019. 
76 Australia, Australian Federal Police, AFP Annual Report 2016-17 
(September 2017). 
77 New Zealand, New Zealand Customs Service, Arrests after meth seizure 
in Christchurch, press release, 16 November 2017. Available at 
www.customs.govt.nz/about-us/news/media-releases/arrests-after-
meth-seizure-in-christchurch/ and Ibid. Kiwi man jailed for importing 
meth and firearm possession, press release, 4 September 2018. Available at 
www.customs.govt.nz/about-us/news/media-releases/kiwi-man- 
jailed-for-importing-meth-and-firearm-possession/
78 Japan, Permanent Mission of Japan to the International Organizations 
Vienna, Latest situation on synthetic drugs and responses to the threats in 
Japan: Part I, presentation held at the 11th Annual Regional SMART 
Workshop in Singapore, August 2019.
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Yokohama seaport.79 Also in 2017, New Zealand Customs 
reported the seizure of 49 kg of methamphetamine, con-
cealed in safety lights, delivered from Mexico by plane in 
November 201780 and in 2019, 110 kg of methampheta-
mine was seized, hidden inside the batteries of golf carts, 
which were exported from the United States with Mexico 
as possible origin.81
Increased involvement in trafficking 
and manufacture in Europe
European countries have recently reported seizure inci-
dents of methamphetamine trafficked from Mexico. For 
instance, in March 2020, the Spanish authorities seized 
752  kg of methamphetamine imported from Mexico, 
which is also believed to have been the largest single 
methamphe tamine seizure in the country to date.82 In May 
2020, Slovakia also reported the largest individual seizure 
of methamphe tamine in the country consisting of 1.5 tons 
believed to have originated from Mexico and trafficked via 
Croatia.83 It is important to note that in both of these cases 
it remains unclear whether Europe was intended as the final 
 destination for the seized methamphetamine or whether 
these shipments were destined for onward trafficking. 
Alongside recent reports of methamphetamine trafficking 
from Mexico, there have been several incidents of Mexican 
nationals being arrested for their involvement in metham-
phetamine manufacture in Europe. For instance, in 2019, 
Mexican nationals were arrested for their involvement in 
methamphetamine manufacture in the Netherlands. In 
that same year, Dutch authorities also suspected Mexican 
criminal networks together with outlaw motorcycle gangs 
to have been connected to a 2.5 ton seizure of metham-
phetamine in Rotterdam.84 When the Dutch National 
79 Japan, Permanent Mission of Japan to the International Organizations 
Vienna, Latest situation on synthetic drugs and responses to the threats in 
Japan: Part I, presentation held at the 10th Annual Regional SMART 
Workshop in Chiang Rai, August 2018.
80 New Zealand, New Zealand Customs Service, Arrests after meth seizure 
in Christchurch, press release, 16 November 2017. Available at 
www.customs.govt.nz/about-us/news/media-releases/arrests-after- 
meth-seizure-in-christchurch/
81 New Zealand, New Zealand Customs Service, Customs seizes 110 kg of 
methamphetamine and handguns, 25 February 2019. Available at 
www.customs.govt.nz/about-us/news/media-releases/customs-seizes- 
110-kg-of-methamphetamine-and-handguns/
82 Spain, Guardia Civil, Desarticulada en Alicante una organización 
criminal que introducía metanfetamina oculta en bloques de mármol, press 
release, 3 March 2020. Available at www.guardiacivil.es/es/prensa/
noticias/7251.html
83 Slovak Republic, Finan ná správa, Zaistili sme 1,5 tony drog z Mexika! 
Záchyt, aký na Slovensku nemá obdobu, press release, 7 July 2020. 
Available at www.financnasprava.sk/sk/pre-media/novinky/archiv-
noviniek/detail-novinky/_1500kg-drog-mx-ts/bc
84 European Monitoring Centre for Drugs and Drug Addiction and 
Europol, Methamphetamine in Europe: EMCDDA-EUROPOL threat 
assessment 2019 (Luxembourg, Publications Office of the European 
Union, 2019).
Police raided a large-scale methamphetamine manu-
facturing facility in the province of Gelderland in May 
2020, nationals from Colombia, Mexico and the United 
States were arrested on the site.85 
The activity of nationals from Mexico and other countries 
in Latin America and the Caribbean in methampheta-
mine manufacture in Europe follows indications of an 
 earlier involvement in West Africa. In Nigeria, a large 
industrial size laboratory was dismantled in 2016, which 
relied on benzaldehyde as a precursor chemical. This indi-
cates a P-2-P (1-phenyl-2-propanone)86-based synthetic 
route, which is not typical for the predominantly 
 ephedrine-based methamphetamine manufactured in 
West Africa, but common in Mexico. Four Mexican 
nationals that are thought to have contributed technical 
expertise to the method of synthesis, and five Nigerian 
nationals were arrested in connection with this  clandestine 
laboratory.87 
Use of non-scheduled precursor chemicals 
of methamphetamine on the increase
Methamphetamine manufacture in Mexico is mainly 
based on P-2-P using the reductive amination method,88 
and there is evidence that the methylamine used in this 
process may be produced locally.89 In general, Mexican 
organized crime groups have been able to quickly adapt 
their synthesis routes in reaction to precursor restrictions, 
for example, by using unscheduled or “designer” precur-
sors.90,91 This is evident in seized samples analysed in the 
United States, which have revealed the use of the nitro-
styrene method, which has been using benzaldehyde and 
nitroethane92 as precursors93 to obtain P-2-P since 
85 Netherlands, Politie, Drie personen aangehouden bij inval groot drugslab, 
press release, 10 May 2020. Available at www.politie.nl/nieuws/2020/
mei/10/11-drie-personen-aangehouden-bij-vondst-groot-drugslab-in-
achter-drempt.html
86 P-2-P is under inter national control.
87 UNODC, Global Synthetic Drugs Assessment 2020 (United Nations 
publication, Sales No. E.20.XI.9).
88 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
89 United States, Department of Justice, Drug Enforcement 
Administration, 2018 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2018).  
90 Designer  precursors are chemical substances made intentionally to 
allow for the manufacture or recovery of scheduled precursors or 
controlled drugs, and usually have no legitimate use.
91 See also: UNODC,  An expanding synthetic drugs market   Implications 
for precursor control, Global SMART Update, vol. 23 (March 2020).
92 Both benzaldehyde and nitroethane are under national control in 
Mexico since October 2015.
93 Isaac Onoka, Andrew Toyi Banyika, Protibha Nath Banerjee, John J. 
Makangara, and Laurence Dujourdyb, “A review of the newly identified 
impurity profiles in methamphetamine seizures”, Forensic Science 
International: Synergy, vol.2, pp.194-205 ( June 2020). 
172. StImuLAntS
mid-2014. More than half of the seized methampheta-
mine samples analysed in the second half of 2017 were 
synthesized with this method.94 
However, the share of methamphetamine manufactured 
with this method decreased significantly among the sam-
ples analysed in the second half of 2018, which saw a 
rebound of methamphetamine manufactured from the 
phenylacetic acid route.95 More recently, Mexican organ-
ized crime groups have been using benzyl cyanide, a pre-
cursor of the inter nationally controlled APAAN 
(alpha-phenylacetoacetonitrile), which can be synthe-
sized from benzyl chloride and sodium cyanide to obtain 
P-2-P.96 None of the three substances, benzyl cyanide, 
benzyl chloride and sodium cyanide, are under inter-
national control. While in Mexico, benzyl cyanide and 
benzyl chloride are controlled under the national 
94 United States, Department of Justice, Drug Enforcement 
Administration, 2018 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2018).
95 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
96 International Narcotics Control Board, Precursors and chemicals frequently 
used in the illicit manufacture of narcotic drugs and psychotropic substances 
2019 (United Nations publication, Sales No. E.20.XI.2). 
precursor legislation,97 this is not the case for sodium cya-
nide.98 In terms of trade value and net weight, Mexico was 
the single largest importer of sodium cyanide worldwide 
from 2015 to 2019. Most of these imports originated 
from the United States, China and the Republic of Korea 
(in descending order of amounts seized).99 Although 
there are many legitimate uses of sodium cyanide, for 
example in gold and silver mining operations,100 it cannot 
be excluded that this chemical is diverted for the illicit 
manufacture of APAAN and P-2-P. In a similar develop-
ment, in recent years, sodium cyanide has increasingly 
been seized in the Golden Triangle in South-East Asia, 
which is the second major area of methamphetamine 
manufacture in the world.101 
97 Mexico, Secretaría de Salud, Ley Federal para el Control de Precursores 
Químicos, Productos Químicos Esenciales y Máquinas para elaborar 
Cápsulas, Tabletas y/o Comprimidos (December 1997).
98 Sale of sodium cyanide (as poisonous substance) is regulated in: 
Mexico, Ley General de la Salud, Artículo 278, Fracción III (1987).
99 As reported for commodity code HS 283711 -  Cyanides and cyanide 
oxides; of sodium  based on United Nations Statistics Division, UN 
Commodity Trade Statistics Database. Available at https://comtrade.
un.org/data
100 International Cyanide Management Institute, Cyanide Facts – Use in 
Mining (n.d.). Available at www.cyanidecode.org/cyanide-facts/
use-mining
101 UNODC, Synthetic Drugs in East and Southeast Asia. Latest 























Not under international control
Placed in Table I  of 1988 Convention 2010-2020
Table I  of 1988 Convention prior to 2010
Schedule II, 1971 Convention
Figure 8 . Precursors for amphetamine and methamphetamine
Source: UNODC elaboration .
*Placed in Table I, 1988 Convention at the sixty-third Commission on Narcotic Drugs, March 2020 .
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Sodium cyanide and benzyl chloride are produced on an 
industrial scale in Mexico for licit purposes, which may 
offer opportunities for their diversion. Since 2017, 
sodium cyanide is produced in a chemical plant in 
Veracruz with an annual production capacity of 40,000 
tons102 and another factory in Durango is under construc-
tion.103 Two benzyl chloride producing factories are 
located in Morelos and the State of Mexico.104 Indeed, 
there have been reports of sodium cyanide thefts in 
Mexico105 and sodium cyanide, benzyl cyanide and benzyl 
chloride have all been discovered in clandestine laborato-
ries.106 Large amounts of precursors have been seized in 
102 Evonik Industries, Officially opened: CyPlus Idesa sodium cyanide 
production in Mexico, press release, 22 February 2017. Available at 
https://corporate.evonik.com/en/media/press-releases/products/
officially-opened-cyplus-idesa-sodium-cyanide-production-in-
mexico-106317.html and Asociación Nacional de la Industria Química, 
Directorio - La Industria Química en México. Cyplus Idesa Sapi de CV, 
(n.d.). Available at https://aniq.org.mx/directorio/Productos-
Quimicos/ empresa-detalle.asp?id=111762
103 The Chemours Company, The Laguna Plant (n.d.). Available at 
www.chemours.com/en/about-chemours/global-reach/laguna
104 Asociación Nacional de la Industria Química, Cloruro de Bencilo, 
(n.d.). Available at https://aniq.org.mx/Directorio/Productos-
Quimicos/lista-empresa-producto.asp?id=1319
105 Mexico, Coordinación Nacional de Protección Civil, Boletín de 
Alerta por robo de Cianuro de Sodio (October 2019). Available at 
https://twitter.com/CNPC_MX/status/1187369318339764230
106 Mexico, Fiscalía General de la República, Comunicado FGR 
DPE/1918/2020. Desmantela la FGR laboratorio clandestino y asegura 
casi tres toneladas de precursores químicos, press release, 9 September 2020 
and Mexico, Fiscalía General de la República, Comunicado FGR 248/20. 
FGR destruye más de 41 mil litros y más de 14 toneladas de sustancias y 
precursores químicos, press release, 8 August 2020. 
other countries as well: For example, in Guatemala, 
between 2018 and March 2020, a total of 572 tons of 
seized precursors such as ethyl phenylacetate, methyl-
amine, sodium hydroxide and sulphuric acid were 
destroyed.107 
The available evidence demonstrates that traffickers use a 
wide range of precursors in the illicit manufacture of 
methamphetamine and are flexible in terms of synthesis 
routes. In that sense, change is a prominent feature. 
Precursors frequently used in the past but no longer in the 
present day may reappear in the future when traffickers 
see advantages in obtaining them for their purposes. 
New psychoactive substances 
with stimulant effects 
NPS with stimulant effects were first reported in the 
region in 2009 by Chile, Colombia and Costa Rica. The 
number of different NPS with stimulant effects reported 
each year increased until 2016 and have levelled off since 
then. Between 2008 and 2020, a total of 86 individual 
NPS with stimulant effects were reported by 12 out of 15 
countries in the region. Brazil reported the highest 
number with 51, followed by Argentina (23) and Chile 
(21) for the same period. 
107 Guatemala, Ministerio de Gobernación, Viceministerio Antinarcótico 
realiza demostración a delegaciones centroamericanas sobre uso de Horno 
Incinerador, press release, 5 March 2020. 
Figure 9 .  Number of new psychoactive substances with stimulant effects in Latin American and 
Caribbean countries (as of December 2020)






















NPS with stimulant effects belong to a wide range of 
 different chemical groups. More than half of the 86 NPS 
with stimulant effects identified in the region were syn-
thetic cathinones. Between 2015 and 2020, Brazil 
reported the highest number of different synthetic cathi-
nones (30), followed by Chile (12) and Colombia (9). 
Overall, methylone and N-ethylnorpentylone were the 
most frequently reported substances for that same period. 
Figure 10 .  Proportion of new psychoactive 
substances with stimulant effects 
by chemical group reported in 
Latin America and the Caribbean 
(as of December 2020)
Source: UNODC, Early Warning Advisory on NPS .
Note: Eleven reporter countries included .
Synthetic cathinones made up the largest share of NPS 
cases in Brazil with 46 per cent and 69 per cent respec-
tively in 2017 and 2018. Although N-ethylpentylone was 
first reported in the country only in 2016, significant sei-
zure amounts, have been reported with a total quantity of 
816 tablets and 29.5 kg of crystals/powder in 2017 and 
5,776 tablets and 74.8 kg of crystals/powder in 2018 
respectively. N-ethylpentylone has also been identified in 
mixtures with other substances such as NPS with hallu-
cinogenic effects, other synthetic cathinones or 
MDMA.108 Synthetic cathinones in particular have been 
sold as “ecstasy” in tablets, powder or crystalline form. In 
Colombia, for instance, “Hello Kitty”-shaped tablets con-
taining butylone were detected in 2017,109 and tablets 
sold as “ecstasy” containing N-ethylnorpentylone, dipen-
tylone, eutylone, and pentylone were seized in 2020.110
In 2016, two benzofurans with stimulant effects, 
4-APB  (4-(2-aminopropyl)benzofuran) and 6-APB 
(6-(2-aminopropyl)benzofuran), were identified in 
Colombia.111 Benzofurans with stimulant effects have 
been detected in Brazil as well, for example, 5-MAPB 
(N-methyl-5-(2-aminopropyl)benzofuran) and 5-EAPB 
(1-(benzofuran-5-yl)-N-ethylpropan-2-amine), which 
were first identified in the country in 2014.112
108 Brazil, Polícia Federal, Synthetic Drugs. 2018 Report, (n.d.). Available 
at www.gov.br/pf/pt-br/acesso-a-informacao/acoes-e-programas/
relatorio-de-drogas-sinteticas-2018/drogas_sinteticas_2018_eng.pdf
109 Colombia, Observatorio de Drogas de Colombia, Detección de nueva 
catinona sintética: comprimidos en forma de Hello Kitty con contenido de 
butilona (Bogotá, 2017).
110 Colombia, Observatorio de Drogas de Colombia, Alerta informativa. 
Comercialización de catinonas sintéticas como éxtasis bajo la presentación 
de polvo y cristales (Molly, MD) (Bogotá, 2020). 
111 Colombia, Observatorio de Drogas de Colombia, Aparición de Nuevas 
Sustancias Psicoactivas en Colombia (Bogotá, 2017).













3 . HALLUCINOGENS AND DISSOCIATIVES
Hallucinogens are a diverse group of substances that induce 
distorted states of consciousness, perception, thinking and 
feeling, accompanied by different degrees of auditory or 
visual hallucinations. On the basis of their mechanism of 
action in the central nervous system, hallucinogens in gen-
eral can be divided into two main groups: classic hallucino-
gens and dissociatives. Classic hallucinogens such as LSD 
are also referred to as “psychedelics”. Dissociatives, for 
example, ketamine, are a group of substances with hallu-
cinogenic and stimulant properties. They inhibit the reup-
take of dopamine, norepinephrine and serotonin, thus 
intensifying the effect of those three neurotransmitters, and 
modulate effects at the N-methyl-D-aspartate (NMDA) 
receptor in the brain and produce feelings of detachment 
and dissociation from the self and the environment.113
Latin America and the Caribbean are rich in plant-based 
hallucinogens which also grow in the region including 
many with traditional uses. However, the focus of this chap-
ter is on synthetic drugs. In this regard, the emergence of 
NPS with hallucinogenic effects poses specific health chal-
lenges in a region with a comparatively high prevalence of 
the use of hallucinogenic drugs as some of them are very 
toxic and can lead to severe and even fatal overdose.
Hallucinogens have a higher 
prevalence than many other drugs
Hallucinogens encompass a large variety of substances, 
from well-known substances such as LSD and ketamine to 
NPS with hallucinogenic effects. Available drug use data 
indicate that the prevalence-of-use rate of hallucinogens is 
higher than that of many other drugs.114 According to a 
drug use study conducted among university students in 
four Andean countries in 2016, hallucinogenic substances 
were found to be the second most used substance after 
cannabis. In Bolivia (Plurinational State of) and Colombia, 
the use of hallucinogenic substances in this study referred 
to LSD, while in Ecuador and Peru it related to the use of 
hallucinogenic mushrooms. More specifically, in Bolivia 
(Plurinational State of) and Colombia, hallucinogenic 
113 UNODC, Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
114 UNODC, responses to the annual report questionnaire.
mushrooms were found to be the third most used drug 
among university students in 2016.115
The availability and use of LSD in particular might be 
increasing among university students in the region. 
According to drug use studies conducted among univer-
sity students in four Andean countries (Bolivia 
(Plurinational State of), Colombia, Ecuador and Peru), 
the lifetime prevalence for LSD use was found to be 
0.5  per cent in 2009, which increased significantly to 
1.7 per cent in 2012 and to 3.8 per cent in 2016. Males had 
a higher annual prevalence-of-use rate than females over 
the eight-year period in these four countries. The lifetime 
prevalence rates among university students, both males 
and females, have risen significantly. While the male 
 student lifetime prevalence rate increased from 0.8 per 
cent in 2009 to 4.8 percent in 2016, the female rate rose 
from 0.2 per cent in 2009 to 2.7 per cent in 2016.116
Figure 11 .  Lifetime prevalence of LSD use rates 
among university students in Bolivia 
(Plurinational State of), Colombia, 
Ecuador and Peru, by sex and total, 
2009–2016
Source: UNODC, III Estudio epidemiológico andino sobre con-
sumo de drogas en la población universitaria, Informe Regional 
2016 (June 2017) . 
115 UNODC, III Estudio epidemiológico andino sobre consumo de drogas en 
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Based on the prevalence rates in 2016, Colombia had the 
highest levels of lifetime (9.5 per cent) and annual preva-
lence of LSD use rates (4.2 per cent) among university 
students, followed by Ecuador, Bolivia (Plurinational 
State of) and Peru.117
Figure 12 .  Lifetime and annual prevalence of 
LSD use rates among university 
students in Bolivia (Plurinational 
State of), Colombia, Ecuador and 
Peru, 2016
Source: UNODC, III Estudio epidemiológico andino sobre 
 consumo de drogas en la población universitaria, Informe 
Regional 2016 (June 2017) .
The perception of ease of access to LSD among university 
students refers to how easy or difficult it is for the student 
to obtain LSD. A larger share of university students in 
Colombia in 2016 found it easier to access LSD than in 
Bolivia (Plurinational State of), Ecuador or Peru. 
Differences in reported ease of access between male and 
female students existed but were less pronounced than in 
the prevalence-of-use rates and not uniform across the 
four countries. 
117 Ibid.
Figure 13 .  Perception of easy access to LSD 
among university students in Bolivia 
(Plurinational State of), Colombia, 
Ecuador and Peru, by sex and total, 
2016  
Source: UNODC, III Estudio epidemiológico andino sobre con-
sumo de drogas en la población universitaria, Informe Regional 
2016 (June 2017) .
Evidence of the use of dissociatives 
(ketamine) among university students
Among university students in the same four Andean 
countries, ketamine was found to be a less frequently used 
drug than LSD, with lifetime prevalence rates ranging 
from 0.43 per cent use in Ecuador and 0.97 per cent use in 
Bolivia (Plurinational State of), and past-year prevalence 
rates at around 0.1 per cent or less across all four countries 
in 2016.118
Figure 14 .  Lifetime prevalence of ketamine use 
rates among university students in 
Bolivia (Plurinational State of), 










































































































Source: UNODC, III Estudio epidemiológico andino sobre con-
sumo de drogas en la población universitaria, Informe Regional 
2016 (June 2017) .
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In a drug use study conducted among university students 
in Costa Rica in 2016, LSD was found to be the second 
most frequently used drug after cannabis, with a lifetime 
prevalence rate of 5.67 per cent use and 3.12 per cent 
annual use. In contrast, ketamine was found to have a life-
time and annual prevalence rate of 0.67 per cent use 
among university students in the country. In terms of 
accessibility, 21 per cent of university students found LSD 
easy to obtain, whereas 7 per cent found ketamine easy to 
access. LSD was also found to be one of the most fre-
quently offered drugs among university students in Costa 
Rica with more than 6 per cent of students reporting to 
have been offered LSD within the last month.119
In El Salvador, a drug use study conducted among school 
students found the lifetime prevalence of both LSD and 
ketamine use to be 0.7 per cent. Among women, ketamine 
was observed to be the drug with the lowest average age of 
initiation.120
Emergence of large numbers of 
synthetic new psychoactive substances 
with hallucinogenic effects 
In recent years, a large variety of NPS with hallucinogenic 
effects have been reported in the region. Between 2013 
and 2015, Colombia reported 2C-E (2,5-dimethoxy- 
4-ethylphenethylamine), 5-MeO-MiPT (5-methoxy-
N- isopropyl-N-methyltryptamine) and seven different 
NBOMe compounds.121 Moreover, in 2019 alone, six 
countries (Argentina, Bolivia (Plurinational State of), 
Brazil, Chile, Colombia and Uruguay) reported three 2C 
series compounds.122 
119 Costa Rica, Instituto Costarricense sobre Drogas, Primer Informe: 
Perfil de consumo de sustancias psicoactivas en el estudiantado de 
universidades públicas en Costa Rica (San José, Editorial Universidad de 
Costa Rica, 2020).
120 El Salvador, Ministerio de Salud, Cuarta encuesta nacional sobre 
consumo de sustancias psicoactivas en población escolar de El Salvador, 2018 









methoxyphenyl)methyl] ethanamine) and 25I-NBOMe (2-(4-iodo-
2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine). Colombia, 
Observatorio de Drogas de Colombia, Aparición de Nuevas Sustancias 
Psicoactivas en Colombia (Bogotá, 2017).
122 2C-C (2,5-dimethoxy-4-chlorophenethylamine), 2C-E and 2C-I 
(2,5-dimethoxy-4-iodophenethylamine). UNODC, Early Warning 
Advisory on NPS.
In Brazil, the share of NPS with hallucinogenic effects 
belonging to the chemical class of  phenethylamines 
among synthetic drug seizure reports has fallen 
from 42.6  per cent in 2015 to only 15.7 per cent in 
2018. This group includes NBOMe compounds, 
NBOH  compounds, DOC (2,5-dimethoxy-4-chloro-
amphetamine)123 and 2C series compounds. 25I-NBOH 
(2-({[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino}
methyl)phenol) was the most frequently encountered 
NPS of this class in 2018 representing 46.3 per cent of 
all reports of phenethylamine-type NPS with hallucino-
genic effects, probably by supplanting previously more 
popular NBOMe compounds.124 2C-B, 25B-NBOMe 
and DOC were also detected in Costa Rica in 2017.125 In 
2017, Chilean authorities identified deschloroketamine, 
a derivative of ketamine.126 In Colombia, allylescaline, a 
 phenethylamine-type NPS with hallucinogenic effects, 
was detected in May 2018.127 
NBOMe compounds vary in potency, pharmacological 
effects and toxicity, and as such errors in dosage may have 
fatal consequences.128 In Colombia and Brazil, fatalities 
have been linked to NBOMe compounds and 25E-
NBOH use.129 Clinical admissions due to intoxications 
from NBOMe compounds were also reported in 
Argentina.130
123 DOC is under inter national control.
124 Brazil, Polícia Federal, Synthetic Drugs. 2018 Report, (n.d.). Available 
at www.gov.br/pf/pt-br/acesso-a-informacao/acoes-e-programas/
relatorio-de-drogas-sinteticas-2018/drogas_sinteticas_2018_eng.pdf
125 Costa Rica, Instituto Costarricense sobre Drogas, Informe de Situación 
Nacional sobre Drogas y Actividades Conexas. Costa Rica 2017 (San 
José, 2018).
126 Chile, Ministerio del Interior y Seguridad Pública, Mesa Nacional de 
Nuevas Sustancias Psicoactivas. Informe No.3 (Santiago, 2017).
127 Colombia, Observatorio de Drogas de Colombia, Hallazgo de dos 
Nuevas Sustancias Psicoactivas (NPS) AMB-FUBINACA y 
ALLILESCALINA (Bogotá, 2018). 
128 UNODC, Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
129 Colombia, Observatorio de Drogas de Colombia, Sistema de Alertas 
Tempranas reporta hallazgo de seis nuevas sustancias psicoactivas y 
aparición de mezclas de hasta cinco sustancias en una misma dosificación, 
press release, 26 October 2017 and Brazil, Instituto-Geral de Perícias, 
Droga sintética que causou morte de jovem é identificada pelo IGP, press 
release, 23 October 2019. Available at https://igp.rs.gov.br/
identificacao-de-nova-droga-sintetica-desafia-o-igp
130 Sociedad Argentina de Medicina et al.,  Recomendaciones 
intersocietarias para cuadros de toxicidad aguda por drogas de diseño, 
Urgencias en la rave.  Revista Argentina de Medicina, vol. 5, supplement 2 
( July 2017).
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Several countries in the region have taken legal measures 
to put hallucinogenic NPS under national control. These 
include Argentina,131 Brazil,132 Chile 133 and Colombia.134
New psychoactive substances with 
hallucinogen effects sold as “LSD”
Adding to the complications and health risks of NPS hal-
lucinogens is the large variety of products containing NPS 
with hallucinogenic effects that have emerged on tradi-
tional illicit drug markets in Latin America and the 
Caribbean. Drug users do not necessarily know if they are 
consuming what they had intended to use or whether 
they end up purchasing an entirely different drug/NPS 
cocktail. For instance, an analysis of 768 LSD samples in 
Colombia between 2014 and 2018 revealed that 56 per 
cent actually contained NBOMe compounds.135 In Brazil, 
the Brazilian Federal Police reported several NBOH and 
NBOMe compounds136 and DOC were detected in seized 
LSD-type blotters and powdered substances. According 
to the Brazilian Federal Police, 25I-NBOH (first identi-
fied in the country in 2016) was found to be the main sub-
stance detected on blotters in 2018.137
Recent data show a decline in the number of countries 
reporting NBOMe compounds in the region. It is unclear 
whether this is linked to an increased availability of LSD 
or the impact of legal controls imposed on several 
NBOMe compounds at the national and inter national 
level, the emergence of NBOH compounds or a combina-
tion of factors. 
131 Argentina, Administración Nacional de Medicamentos, Alimentos y 
Tecnología Médica, Listado de Sustancias Controladas Decreto 772/2015 
(2015). Available at www.anmat.gob.ar/ssce/Decreto_772-15.pdf
132 Brazil, Ministério da Saúde, Agência Nacional de Vigilância Sanitária, 
RESOLUÇÃO - RDC Nº 372 (15 April 2020). Available at www.in.gov.br/
en/web/dou/-/resolucao-rdc-n-372-de-15-de-abril-de-2020-252726528
133 Chile, Biblioteca del Congreso Nacional de Chile, Decreto 867 
- Aprueba reglamento de la ley Nº 20.000 que sanciona el tráfico 
ilícito de estupefacientes y sustancias psicotrópicas y sustituye la ley 
Nº 19.366 (February 2008). Available at www.bcn.cl/leychile/
navegar?idNorma=269323
134 Colombia, Ministerio de Salud y Protección Social, Resolución Número 
0000315 de 2020 (March 2020). Available at www.minsalud.gov.co/
Normatividad_Nuevo/Resoluci%C3%B3n%20No.%200315%20de% -
202020.pdf
135 Échele Cabeza, Alerta LSD-NBOMe, press release, 24 January 2018. 
136 As 25B-NBOH, 25C-NBOH, 25E-NBOH, 25I-NBOH, 25H-
NBOH, 25I-NBOMe and N-acetyl 25I-NBOMe.
137 Brazil, Polícia Federal, Synthetic Drugs. 2018 Report, (n.d.). Available 
at www.gov.br/pf/pt-br/acesso-a-informacao/acoes-e-programas/
relatorio-de-drogas-sinteticas-2018/drogas_sinteticas_2018_eng.pdf
Figure 15 .  NBOMe compounds in Latin 
 America and the Caribbean, by 
number of countries reporting, 
2015–2019 
Source: UNODC, Early Warning Advisory on NPS .
The content of products sold as “LSD” in the region varied 
greatly. For instance, the Chilean Institute of Public 
Health reported the detection of several LSD deriva-
tives138 in blotter stamps in 2017, a form of presentation, 
which is typically associated with LSD and likely to be 
obtained by users intending to get LSD.139 In Uruguay, 
fentanyl was detected in seized stamps in 2017, 140 which 
was also the case in Brazil in 2018.141 In Colombia, DOC 
and DOI (2,5-dimethoxy-4-iodoamphetamine) were 
found in stamps in 2017.142 In Argentina, DOI and 
25I-NBOMe were reportedly found in stamps in 2018.143 
Brazil has also reported the discovery of hallucinogenic 
138 ETH-LAD ((6aR,9R)-N,N,7-triethyl-4,6,6a,7,8,9-hexahydroindolo-
[4,3-fg]quinoline-9-carboxamide), 1P-LSD (N,N-diethyl-7-methyl- 
4-propionyl-4,6,6a,7,8,9-hexahydroindolo[4,3-i]quinoline-9-
carboxamide), AL-LAD ((6aR,9R)-7-allyl-N,N-diethyl-4,6,6a,7,8,9-
hexahydroindolo[4,3-fg]quinoline-9-carboxamide) and 1M-LSD 
((6aR,9R)-N,N-diethyl-4,7-dimethyl-4,6,6a,7,8,9-hexahydroindolo 
[4,3-fg]quinoline-9-carboxamide).
139 Chile, Ministerio del Interior y Seguridad Pública, Mesa Nacional de 
Nuevas Sustancias Psicoactivas. Informe No.3 (Santiago, 2017).
140 Uruguay, Observatorio Uruguayo de Drogas, Sistema de Alerta 
Temprana, Presencia de sellos de LSD adulterados con fentanilo, press 
release, 31 May 2017. Available at https://sat.presidencia.gub.uy/
alertas-publicas/presencia-de-sellos-de-lsd-adulterados-mayo-2017/.
141 Brazil, Polícia Federal, Synthetic Drugs. 2018 Report, (n.d.). Available 
at www.gov.br/pf/pt-br/acesso-a-informacao/acoes-e-programas/
relatorio-de-drogas-sinteticas-2018/drogas_sinteticas_2018_eng.pdf
142 Jenny Fagua Duarte, Sistema de Alertas Tempranas de drogas de 
Colombia, presentation held at the 61 OAS/CICAD regular session in 
Washington, D.C., 21 April 2017. Available at www.cicad.oas.org/
cicaddocs/Document.aspx?Id=4190
143 Observatorio Interamericano sobre Drogas/Comisión 
Interamericana para el Control del Abuso de Drogas,  Datos del Sistema 





























NPS mixtures involving synthetic cathinones or MDMA 
according to the study published in 2018.144 
“Pink cocaine”– a drug with 
varying content
In recent years, several countries in the region have 
reported 2C-B being sold under the brand name “pink 
cocaine”. However, “pink cocaine” (sometimes also 
referred to as “tuci” or “tucibi” in the region) products do 
not necessarily contain 2C-B but often combinations of 
substances other than 2C-B, such as MDMA, cocaine, 
ketamine or other NPS. 145 For instance, in Chile, no 2C-B 
was found in the samples submitted as “2C-B” in recent 
years. Instead, all tested samples contained ketamine, 
sometimes in combination with cocaine, HCl or MDMA 
and caffeine.146 Generally, an increasing number of coun-
tries have reported 2C compounds in Latin America and 
the Caribbean in recent years but not enough is known 
about their commercialization.
Figure 16 .  2C-compounds in Latin America 
and the Caribbean, by number of 
countries reporting, 2015–2019 
Source: UNODC, Early Warning Advisory on NPS .
144 Brazil, Polícia Federal, Synthetic Drugs. 2018 Report, (n.d.). Available 
at www.gov.br/pf/pt-br/acesso-a-informacao/acoes-e-programas/
relatorio-de-drogas-sinteticas-2018/drogas_sinteticas_2018_eng.pdf
145 UNODC, Global SMART Newsletter for Latin America and the 
Caribbean, Issue No. 5 (October 2019). Available at https://mailchi.
mp/c70560380b45/lacnewslettervol5-372887
146 Ibid. and Chile, Ministerio Publico de Chile Fiscalía, Observatorio del 
narcotráfico – Informe 2020 (May 2020). 
Hallucinogens are seized across 
Latin America and the Caribbean
In recent years, LSD seizures have been reported by several 
countries in Latin America and the Caribbean. Interpreting 
LSD seizure amounts reported in kg equivalent has severe 
limitations as the drug is seized in a large variety of forms of 
presentation, ranging from liquids over tablets to impreg-
nated blotter paper stamps. In addition, the drug is active at 
the microgram level so that seemingly small amounts may 
translate into tens of thousands of doses. Between 2015 and 
2019, over 8 kg of LSD were seized in the region. An 
increasing number of LSD seizure cases was reported in 
Argentina between 2015 and 2019.
Figure 17 .  LSD seizure cases reported in 
Argentina, 2015–2019
Source: UNODC, responses to the annual report questionnaire .
Between 2015 and 2019, 36 kg of hallucinogens other 
than LSD (NBOMe compounds,147 2C-B, DMT (N,N-
dimethyltryptamine), mescaline, psilocybine) 148 were 
seized in Argentina, Chile, Colombia and Costa Rica. In 
Colombia, an increasing number of seizure cases of hallu-
cinogens other than LSD were observed between 2015 
and 2019.149
147 25B-NBOMe, 25C-NBOMe and 25I-NBOMe are under inter-
national control.
148 2C-B, DMT, mescaline and psilocybine are under inter national 
control.


















































26 SYNTHETIC DRUGS AND NEW PSYCHOACTIVE SUBSTANCES IN LATIN AMERICA AND THE CARIBBEAN 2021
Figure 18 .  Hallucinogen seizure cases other 
than LSD reported in Colombia, 
2015–2019  
Source: UNODC, responses to the annual report questionnaire . 
Note: In terms of substances, these cases refer to 25I-NBOMe 
and 2C-B . 
Ketamine is of growing concern
Particularly in Costa Rica, ketamine has emerged as a 
drug of concern and was placed under national control in 
2015.150 In February 2017, Costa Rican authorities, for 
the first time, arrested drug traffickers for selling ketamine 
(in addition to cocaine, marijuana and crack).151 From 
January to October 2017, authorities reported having 
seized almost 800 bottles of ketamine in Costa Rica close 
to the Nicaraguan border.152 In Chile, authorities also 
reported seized ketamine solutions in beverage bottles, 
which are suspected to have been trafficked from Bolivia 
(Plurinational State of) and Peru.153
Overall, seizure amounts of ketamine seem to be on the 
rise in the region. Between 2015 and 2019, Argentina, 
Chile, Costa Rica, Panama, Uruguay and Venezuela 
(Bolivarian Republic of) have all reported ketamine sei-
zures in one or more years, however, in terms of amounts, 
the bulk is made up by Argentina and Chile.
150 Costa Rica, Ministerio de Salud, Comunicado de prensa, press release, 
30 September 2015. Available at www.ministeriodesalud.go.cr/index.
php/noticias/noticias-2015/799-comunicado-de-prensa-ketamina
151 Costa Rica, Ministerio de Seguridad Pública, PCD del Ministerio de 
Seguridad Pública confirma primer caso de venta comprobada de Ketamina 
como droga recreativa y desarticula red narcotraficante local, press release, 
24 February 2017. Available at www.seguridadpublica.go.cr/sala_
prensa/comunicados/2017/febrero/CP0315.aspx
152 Costa Rica, Ministerio de Seguridad Pública, Policía de Fronteras 
decomisa millonario cargamento de ketamina a prófuga de la Justicia de 
Costa Rica y Nicaragua, press release, October 2017. Available at 
www.seguridadpublica.go.cr/sala_prensa/comunicados/2017/
Octubre/CP1388.aspx
153 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del 
narcotráfico – Informe 2020 (May 2020). 
Figure 19 .  Ketamine seizures reported in 
Latin America and the Caribbean, 
 2015-2019 
Source: UNODC, responses to the annual report questionnaire .
Note: Six reporter countries included .
Emerging production of 
hallucinogenic drugs
In recent years, hallucinogens such as LSD have been traf-
ficked to the region from European countries. Most com-
monly, there have been reports of hallucinogens being 
trafficked from Belgium and Germany to Argentina and 
Brazil.154 In addition to hallucinogens being trafficked 
to the region, facilities to manufacture hallucinogenic 
drugs have also been discovered by authorities within 
the region. In Chile, authorities dismantled a  laboratory 
manu facturing stamps impregnated with NBOMe 
compounds and 5-MeO-DIPT (5-Methoxy-N,N-
diisopropyltryptamine), a tryptamine often sold under 
the brand name “foxy”.155 In 2017, the Chilean police 
also dismantled a processing facility that had been manu-
facturing 25I-NBOMe blotter stamps.156 Furthermore, 
in 2018, the Chilean authorities reported to have seized 
LSD tartrate, which had been smuggled from the United 
States and is suspected to have been intended for produc-
tion of LSD stamps in Chile.157 The clandestine synthesis 
of substances with hallucinogenic effects has not yet been 
reported. 
154 United States, Department of State, International Narcotics Control 
Strategy Report. Volume 1. (Washington D.C., 2020) and Observatorio 
Interamericano sobre Drogas/Comisión Interamericana para el Control 
del Abuso de Drogas,  Datos del Sistema de Alerta Temprana para las 
Américas , Boletín Informativo, Vol. 1 (2020). 
155 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del 
narcotráfico – Informe 2020 (May 2020). 
156 UNODC,  Chile: Police dismantle clandestine laboratory suspected 
of manufacturing 25I-NBOMe , Early Warning Advisory Newsclip, July 
2017. Available at www.unodc.org/LSS/Announcement/Details/
a8614a66-e3f5-40a7-b707-f03b8ea3201d
157 Chile, Ministerio Publico de Chile Fiscalía, Observatorio del 
















































4 . SYNTHETIC CANNABINOID RECEPTOR AGONISTS
Synthetic cannabinoids bear structural features that allow 
binding to one of the known cannabinoid receptors in the 
central nervous system and produce effects similar to 
those of THC (delta-9-tetrahydrocannabinol), the princi-
pal psychoactive component of cannabis.158 
A total of 36 different synthetic cannabinoid receptor 
agonists have been identified by seven countries in the 
region between 2009 and 2019159 but the number of dif-
ferent synthetic cannabinoid receptor agonists reported 
per year has markedly declined since 2016.160 Notably, 
the previously prominent JWH161 series compounds were 
not reported after 2017, and may have been displaced by 
newer generation substances. Unlike in other regions of 
the world, where synthetic cannabinoids continue to con-
stitute one of the largest and most diverse groups of NPS, 
in Latin America and the Caribbean, in 2018 and 2019, 
only five different synthetic cannabinoids were reported 
from only two countries, Brazil and Argentina, only one 
of them (5F-MDMB-PINACA (methyl 2-(1-(5-fluoro-
pentyl)-1H-indazole-3-carboxamido)-3,3-dimethyl- 
butanoate ))162 in both countries.163
158 UNODC, Effect Groups of NPS (February 2020). Available at 
www.unodc.org/documents/scientific/NPS-poster_WEB_2020.pdf
159 UNODC, Early Warning Advisory on NPS.
160 UNODC, Global Synthetic Drugs Assessment 2020 (United Nations 
publication, Sales No. E.20.XI.9).
161 JWH-018 ((1-Pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone) 
and AM-2201 ([1-(5-Fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-
methanone) are under inter national control.
162 5F-MDMB-PINACA is under inter national control.
163 UNODC, Early Warning Advisory on NPS.
Figure 20 .  Synthetic cannabinoid receptor 
agonists reported to UNODC in 
Latin America and the Caribbean, 
2009–2019 (as of December 2020)
Source: UNODC, Early Warning Advisory on NPS .
In terms of use, among university students in Bolivia 
(Plurinational State of), Colombia, Ecuador and Peru, 
the lifetime prevalence use rate for synthetic cannabi-
noids ranged between 0.5 per cent (Peru) and 4.2 per cent 
(Colombia) in 2016. In Colombia and Ecuador, male 
 university students had a significantly higher lifetime 
prevalence-of-use rate (6.4 per cent and 2.7 per cent, 
respectively) than female students (2.3 per cent in 
Colombia and 0.7 per cent in Ecuador). However, in 
Bolivia (Plurinational State of) and Peru, the gender gap 
was less pronounced.164
164 UNODC, III Estudio epidemiológico andino sobre consumo de drogas en 
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Figure 21 .  Lifetime prevalence of synthetic 
cannabinoid use rates among 
university students in Bolivia 
(Plurinational State of), Colombia, 
Ecuador and Peru, by sex and 
total, 2016
Source: UNODC, III Estudio epidemiológico andino sobre con-
sumo de drogas en la población universitaria, Informe Regional 
2016 (June 2017) .
In Chile, the only country in the region for which annual 
prevalence of use of synthetic cannabinoids (locally 
knows as “marihuana sintética”) among the general popu-
lation is available, the rate has increased from 0.5 per cent 
(2014) to 1.1 per cent (2018). While the male annual 
prevalence-of-use rate increased strongly from 0.7 per 
cent in 2014 to 1.7 per cent in 2018, the female rate 
remained relatively stable at 0.4 per cent in 2014 and 
0.5  per cent in 2018. In 2018, the annual prevalence 
among young people, between 19 and 25 years of age, was 
more than three times higher than in the general 
 population with 3.9 per cent.165 
165 Chile, Observatorio Chileno de Drogas, Décimo Tercer Estudio 
Nacional de Dragas en Población General de Chile, 2018 (Santiago, 2019).
Several countries including Argentina, Brazil, Costa Rica, 
Mexico, Panama and Uruguay have reported the identifi-
cation of synthetic cannabinoids but information on 
prevalence of use is not available. Urine screening tests 
during a music festival in Uruguay in 2015 showed that 
11 per cent of the samples contained synthetic cannabi-
noids.166 Screening in subsequent years for the same panel 
of target substances did not show positive results, which, 
however, does not preclude the presence of newer genera-
tion synthetic cannabinoids, which were not targeted in 
the analysis.167 Synthetic cannabinoids seem to be used in 
Brazilian penitentiaries. According to media reports, 
prison authorities in São Paulo intercepted 1,821 attempts 
to smuggle a synthetic cannabinoid product labelled “K4” 
into prisons.168 
Figure 22 .  Synthetic cannabinoid receptor 
agonists reported to UNODC in 
Latin American and Caribbean 
countries (as of December 2020) 
Source: UNODC, Early Warning Advisory on NPS .
166 Uruguay, Observatorio Uruguayo de Drogas, Sistema de Alerta 
Temprana, Informe Especial: Cannabinoides Sintéticos (Montevideo, 
2017).
167 Uruguay, Unidad de Medioambiente, Drogas y Doping, Instituto Polo 
Tecnológico de Pando, Facultad de Química, Informe Final: Screening de 
nuevas sustancias psicoactivas, THC y cocaína en muestras de orina 
obtenidas en una fiesta musical en el área metropolitana (Montevideo, 
2018).
168 César Galvão, “Polícia Científica de SP começa a fazer laudos que 






















































































5 . SEDATIVES AND HYPNOTICS 
Sedatives/hypnotics are central nervous system depres-
sants, that suppress, inhibit or decrease brain activity, with 
actions derived from their activation of receptors in the 
GABA receptor complex in the brain to produce sedative, 
hypnotic, anxiolytic, anticonvulsant and muscle relaxant 
effects. Many sedatives/hypnotics belong to the benzo-
diazepine group of substances.169 In the context of 
 population-based surveys on self-reported drug use in the 
region, the term “tranquilizers” is understood to include 
sedatives/hypnotics.
Non-medical use of tranquilizers
Besides non-medical use of pharmaceutical opioids, the 
region is also experiencing non-medical use of prescrip-
tion stimulants and tranquilizers. These drugs are easier to 
access, especially in countries where oversight on distri-
bution and prescribing practices may be insufficient, and 
where their non-medical use is less stigmatized compared 
to the use of drugs.170 
Among 10 countries171 that provided information in the 
past decade, the annual prevalence of use of pharmaceuti-
cal stimulants without prescription in the general popula-
tion was below 0.5 per cent, except for Costa Rica, which 
reported 1.71 per cent in 2015. Among university stu-
dents in Bolivia (Plurinational State of), Colombia, 
Ecuador and Peru, the annual prevalence rates for use of 
stimulants without a medical prescription ranged from 
0.16 per cent (Peru) to 0.6 per cent (Ecuador) in 2016.172 
Available data indicate that the rates are higher among 
high school students.173 
169 UNODC, Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
170 Bridgette Peteet and others,  Transnational trends in prescription 
drug misuse among women: A systematic review, International Journal of 
Drug Policy, vol. 63, pp. 56 73 ( January 2019).
171 Argentina (2017), Bolivia (Plurinational State of) (2014), Chile 
(2016), Colombia (2013), Costa Rica (2015), El Salvador (2014), 
Guyana (2016), Jamaica (2016), Panama (2015) and Uruguay (2014).
172 UNODC, III Estudio epidemiológico andino sobre consumo de drogas en 
la población universitaria, Informe Regional 2016 ( June 2017). 
173 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
In Brazil, Costa Rica, Peru and Uruguay, tranquilizers 
rank among the three most prevalent non-medically used 
drugs in recent years. The annual prevalence rates 
throughout the region from 2014 to 2019 ranged between 
0.5 per cent and 2.7 per cent.174 Among university stu-
dents in Bolivia (Plurinational State of), Colombia, 
Ecuador and Peru in 2016, annual prevalence rates were 
between 1.16 per cent (Bolivia (Plurinational State of)) 
and 1.82 per cent (Colombia).175 Among high school stu-
dents, higher use rates have been observed. For instance, 
in 2018, 5.1 per cent of Uruguayan secondary school stu-
dents had used tranquilizers without a prescription in the 
past year,176 and in 2017, the annual prevalence rate was 
8.6 per cent among the Chilean school population177 and 
3.2 per cent among Peruvian high school students.178 Self-
medication seems to be common. For example, in 
Uruguay in 2018, 21 per cent of all people who had taken 
tranquilizers within the last 12 months had not had a pre-
scription for them,179 and in a study in a Peruvian hospital 
in 2019, 45 per cent of benzodiazepine users had been 
self-medicating with no valid prescription for the 
medication.180 
174 UNODC, Global Synthetic Drugs Assessment 2020 (United Nations 
publication, Sales No. E.20.XI.9). 
175 UNODC, III Estudio epidemiológico andino sobre consumo de drogas en 
la población universitaria, Informe Regional 2016 ( June 2017).
176 Uruguay, Junta Nacional de Drogas, Observatorio Uruguayo de 
Drogas, VIII Encuesta Nacional sobre Consumo de Drogas en estudiantes de 
Enseñanza Media. Informe de investigación. Año 2020 (Montevideo, 
2020).
177 Chile, Observatorio Chileno de Drogas, Décimo Segundo Estudio 
Nacional de Drogas en Población Escolar de Chile, 2017 (Santiago, 2018). 
178 Peru, Comisión Nacional para el Desarrollo y Vida sin Drogas, Estudio 
Nacional sobre Prevención y Consumo de Drogas en Estudiantes de 
Secundaria 2017 (Lima, 2019).
179 Uruguay, Junta Nacional de Drogas, Observatorio Uruguayo de 
Drogas, VII Encuesta Nacional sobre Consumo de Drogas en Población 
General. Informe de investigación. Año 2019 (Montevideo, 2019). 
180 John Klauss Cabanillas Tejada, “Automedicación con Benzodiacepinas 
y Riesgo de Abuso en Adultos. Hospital San Juan de Lurigancho 2019”, 
Master thesis, Universidad San Martin de Porres, 2020. Available at 
http://repositorio.usmp.edu.pe/bitstream/handle/20.500.12727/6433/
cabanillas_tjk.pdf?sequence=1&isAllowed=y
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Gender differences of non-medical 
tranquilizer use are pronounced 
While non-medical use of prescription medicines exists 
among both men and women, gender differences are 
more pronounced compared to other drugs. Similar to 
the global situation, the non-medical use of tranquilizers 
is high among women in Latin America and the 
Caribbean.181 The annual prevalence rate of the non- 
medical use of tranquilizers between 2014 and 2019 in 
the general population was higher among women 
 compared to men in 7 out of 8 countries in the region that 
reported data. The annual prevalence-of-use rate for 
women ranged between 0.3 and 3.1 per cent and for men 
between 0.3 and 2.3 per cent.
Furthermore, among secondary school students aged 15 
to 16, the non-medical use of tranquilizers is particularly 
widespread in the region, with past-year prevalence levels 
181 UNODC, World Drug Report 2018 (United Nations publication, 
Sales No. E.18.XI.9). 
of use ranging from 1.1 to 8.8 per cent. The pattern of use 
is most closely associated with females. Of the 11 coun-
tries reporting non-medical use of tranquilizers between 
2014 and 2018, only Venezuela (Bolivarian Republic of) 
reported a higher annual prevalence rate in the school 
population among boys than girls. The annual prevalence 
rate of use for girls ranged between 1.1 and 10.1 per cent 
and for boys between 0.95 and 7.5 per cent. A similar 
trend can be observed among university students. In five 
countries in South America (Bolivia (Plurinational State 
of), Colombia, Ecuador, Peru and Uruguay), which have 
data on past-year use of tranquilizers between 2015 and 
2016, the non-medical use of tranquilizers was higher 
among females. While past-year prevalence of use among 
university students was less than 2 per cent in 4 out of 5 
countries, in 2015 Uruguay notably reported past-year 
prevalence of the use of tranquilizers among university 
students at 6.3 per cent, with 7.7 per cent among female 
students and 4.5 per cent among male students.182
182 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
Figure 23 .  Annual prevalence of non-medical use of tranquilizers and sedatives among the 
general population, in selected Latin American and Caribbean countries, by sex 
and  total, 2014–2018
Source: UNODC, response to the annual report questionnaire . 
Note: The graph represents the latest period available (2014-2018) disaggregated by sex . The general population in Argentina, Chile 
and Uruguay refers to 15-64/65 aged persons and in Bolivia (Plurinational State of), Costa Rica, El Salvador, Mexico and Panama to 














































315. SEdAtIVES And HYPnOtICS 
Figure 24 .  Annual prevalence of non-medical use of tranquilizers and sedatives among 
the school population, in selected Latin American and Caribbean countries, 
by sex and total, 2014–2018  
Source: UNODC, responses to the annual report questionnaire . 
Note: The graph represents the latest estimate available . The school population refers to 15-16-year-old students . 
New psychoactive substances with 
sedative/hypnotic effects emerge
Given the relatively widespread non-medical use of tran-
quilizers in the region, the emergence of benzodiazepine- 
type NPS may not be surprising. Up to December 
2020, Brazil, Chile and Paraguay had reported four 
benzodiazepine- type NPS: the alprazolam triazolo-
benzophenone derivative, etizolam183, flualprazolam184 
and flunitrazolam.185 Still, the illicit market seems to be 
mainly supplied by diverted, licit medications.186 
Among university students in Bolivia (Plurinational State 
of), Colombia, Ecuador and Peru, the annual prevalence 
rate of tranquilizer use is significantly higher than of stim-
ulant use in 2016. All four Andean countries reported an 
annual prevalence rate of tranquilizer use of more than 
1  per cent and a rate of stimulants use of below 0.5 per 
cent (except Ecuador with 0.6 per cent).
183 Etizolam has been under inter national control since November 2020.
184 Flualprazolam has been under inter national control since November 
2020.
185 UNODC, Early Warning Advisory on NPS.
186 Organization of American States, Secretariat for Multidimensional 
Security, Inter-American Drug Abuse Control Commission, The Report 
on Drug Use in the Americas 2019 (Washington D.C., 2019).
Figure 25 .  Annual prevalence of non-medical 
use of tranquilizers and 
 prescription stimulants among 
university students in Bolivia 
(Plurinational State of), Colombia, 
Ecuador and Peru, 2016
Source: UNODC, III Estudio epidemiológico andino sobre con-
sumo de drogas en la población universitaria, Informe Regional 
2016 (June 2017) . 
In Chile (2018), more than a third of users of tranquiliz-
ers reported their source to be friends or family; however, 
the percentage of people who indicated that they had had 
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in 2016 to 18 per cent in 2018.187 Similarly, 30 per cent of 
students using tranquilizers in El Salvador (2018) got the 
drugs from family members.188 In 2018, two thirds of 
Uruguayan high school students that were using tran-
quilizers without prescription obtained them either 
187 Chile, Observatorio Chileno de Drogas, Décimo Segundo Estudio 
Nacional de Drogas en Población Escolar de Chile, 2017 (Santiago, 2018).
188 El Salvador, Ministerio de Salud, Cuarta encuesta nacional sobre 
consumo de sustancias psicoactivas en población escolar de El Salvador, 2018 
(San Salvador, 2019).
through their parents or from their home.189 Preliminary 
data indicate that non-medical use of prescription medi-
cations and especially tranquilizers has increased during 
the quarantine imposed by the COVID-19 pandemic in 
several countries.190 
189 Uruguay, Junta Nacional de Drogas, Observatorio Uruguayo de 
Drogas, VIII Encuesta Nacional sobre Consumo de Drogas en estudiantes de 
Enseñanza Media. Informe de investigación. Año 2020 (Montevideo, 
2020).   
190 Jorge Ameth Villatoro Velázquez, Las Drogas durante el Confinamiento: 
Una mirada hacia distintas fuentes de información, presentation held at the 
capacity-building workshop of OAS/CICAD, 8 July 2020 and Chile, 
Ministerio del Interior y Seguridad Publica, Encuesta online efectos del 
COVID-19 en el uso de alcohol y otras drogas en Chile. Principales 
Resultados ( July 2020).
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6 . SYNTHETIC OPIOIDS
Synthetic opioids are synthetic compounds which are 
derived from opiates (e.g., codeine or morphine) but are 
not opiates themselves. This group includes fentanyl and 
its analogues as well as a range of other structurally diverse 
substances with opioid effects. Their effects are mediated 
through their interaction with opioid receptors and inhib-
itory neurotransmitters. Opioid receptors are responsible 
for triggering brain reward systems and producing analge-
sia (pain relief).191  
The annual prevalence of the non-medical use of syn-
thetic opioids192 in 2018 was found to be 0.19 per cent for 
the South American region, which is significantly below 
the global annual estimate of 1.16 per cent for the same 
year. 193 Subregional estimates for non-medical use of syn-
thetic opioids in the Caribbean and Central American 
region are not available. Due to the paucity of prevalence 
data for these subregions, the extent of synthetic opioid 
use in the region is unclear. Generally, the non-medical 
use of synthetic opioids, such as fentanyl and tramadol, 
appears to be comparatively low and may be limited to 
specific user groups who have access to these 
substances.194 
Is the non-medical use of 
pharmaceutical opioids increasing?
However, recent reports show that synthetic opioids have 
been identified in products sold as heroin and LSD, which 
suggests that drug users in the region are consuming syn-
thetic opioids without their knowledge. For instance, a 
study conducted in northern Mexico found that 93 per 
cent of white powder heroin samples collected from 89 
heroin users contained fentanyl.195 Also, in 2017, the early 
191 UNODC, Terminology and Information on Drugs (United Nations 
publication, Sales No. E.16.XI.8).
192 Includes opiates and prescription opioids such as oxycodone, 
hydrocodone, among others.
193 See annex of the World Drug Report 2020 in UNODC, World Drug 
Report 2020 (United Nations publication, Sales No. E.20.XI.6).
194 Organization of American States/Inter-American Drug Abuse 
Control Commission, Opioids in Latin America ( July 2020). 
195 Clara Fleiz et al., “Fentanyl is used in Mexico’s northern border: 
current challenges for drug health policies.” Addiction, vol. 115, issue 4, 
pp. 778  781 (April 2020). 
warning system in Uruguay reported that fentanyl had 
been detected in samples of drug products in a form of 
presentation typical for LSD.196 Given that drug users 
might be consuming synthetic opioids without their 
knowledge, synthetic opioid use is likely to be underre-
ported in the region.197  
To some extent, treatment figures in some countries may 
reflect a growing non-medical use of pharmaceutical opi-
oids in Latin America and the Caribbean and its severe 
negative health implications. A study conducted by OAS/
CICAD in 2019 identified the emergence of non-medical 
use of pharmaceutical opioids, such as tramadol, mor-
phine and suboxone, in the region and found that it is 
associated with serious negative health implications.198 
Over the past decade, Chile, Costa Rica and Mexico 
reported an increase in the number of people seeking 
treatment for the use of pharmaceutical opioids.
Figure 26 .  Number of persons seeking 
 treatment for the non-medical use 
of pharmaceutical opioids in Chile, 
Costa Rica and Mexico, 2010–2019
Source: UNODC, responses to the annual report questionnaire .
196 Uruguay, Observatorio Uruguayo de Drogas, Sistema de Alerta 
Temprana, Presencia de sellos de LSD adulterados con fentanilo – Mayo 2017, 
press release, 31 May 2017. Available at https://sat.presidencia.gub.uy/
alertas-publicas/presencia-de-sellos-de-lsd-adulterados-mayo-2017/
197 Organization of American States/Inter-American Drug Abuse 
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Emergence of new psychoactive 
substances with opioid 
effects in the region
The analysis of the opioid situation in the region is further 
complicated by the emergence of NPS with opioid effects. 
By December 2020, four countries (Bolivia (Plurinational 
State of), Brazil, Chile and Colombia) reported to have 
identified NPS with opioid effects. So far, there is not 
enough information and data available to determine 
whether users actively seek NPS with opioid effects or 
whether they buy and consume them unintentionally.
Table 2 .  New psychoactive substances with 
opioid effects identified in Latin 
















Source: UNODC, Early Warning Advisory on NPS .
Note: Four reporter countries included .
Fentanyl is trafficked from 
Mexico to the United States
An amount of 362 kg of fentanyl were seized in Mexico in 
2018 and 206 kg in 2019. Another 0.25 kg was seized in 
Argentina in 2017. However, in 2018, the United States 
seized an aggregated annual amount of more than 2.5 tons 
of fentanyl that was suspected to have originated from 
either Mexico or China.199 In a single seizure in January 
2019, United States authorities seized approximately 
115  kg of fentanyl, along with approximately 179 kg of 
methamphetamine, from a Mexican national at the Port 
of Nogales in Arizona.200 According to the United States 
199 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
200 United States, Customs and Border Protection, CBP Officers Seize 
Largest Amount of Fentanyl in CBP History, press release, 31 January 2019.
authorities, fentanyl originating from Mexico is primarily 
being trafficked to the country via on-land routes.201
According to the DEA, the Mexican Sinaloa and the 
Jalisco Nueva Generación cartels are involved in the pro-
duction of fentanyl in Mexico.202 However, there are indi-
cations that fentanyl is also being manufactured or 
processed in other parts of Latin America and the 
Caribbean. For instance, in 2017, authorities in the 
Dominican Republic dismantled a clandestine fentanyl 
laboratory203 which might be connected to trafficking 
 networks in Mexico that intended to distribute it in 
the United States.204
Trafficking of fentanyl precursors 
to Mexico diversifies
According to information from United States authorities, 
the illicit manufacture of fentanyl in Mexico relies mostly 
on the  Janssen  synthesis route, which is more complex 
and takes more time than the previously popular  Siegfried 
route. 205 However, the  Janssen  method has the advantage 
that the precursors NPP (N-phenethyl-4-piperidone) 
and ANPP (4-anilino-N-phenethylpiperidine) are not 
required, substances which were placed under inter-
national control in 2017. 
In addition, the use of the non-scheduled precursor 4-AP 
(4-anilinopiperidine) as an alternative precursor chemi-
cal to NPP for the synthesis of ANPP has recently been 
noted.206 In October 2020, 71 kg of 4-AP originating from 
China were detected at Guadalajara Airport207 and in 
December 2020, another 55 kg of 4-AP from China were 
seized at the same airport.208 
201 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
202 United States, Department of Justice, Drug Enforcement 
Administration,  Fentanyl Flow to the United States , DEA Intelligence 
Report ( January 2020). 
203 International Narcotics Control Board, Report of the International 
Narcotics Control Board for 2018 (United Nations publication, Sales No. 
E.19.XI.2).
204 United States, Department of Justice, Drug Enforcement 
Administration, 2019 National Drug Threat Assessment (Springfield, 
Strategic Intelligence Section, 2020).
205 Ibid. 
206 UNODC,  An expanding synthetic drugs market – Implications for 
precursor control, Global SMART Update, vol. 23 (March 2020).
207 Mexico, Fiscalía General de la República, Comunicado FGR/
DPE/2167/2020. Asegura la Policía Federal Ministerial en Jalisco precursor 
químico procedente de China, press release, 17 October 2020. 
208 Mexico, Fiscalía General de la República, Comunicado FGR/
DPE/2473/2020. Asegura la PFM en Jalisco precursor químico procedente 
de China, press release, 8 December 2020. 
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Figure 27 .  Selected methods for the synthesis of fentanyl
Source: UNODC, “An Expanding Synthetic Drugs Market – Implications for Precursor Control”, Global SMART Update, vol . 23 
(March 2020) .
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7 .  GENERAL TRENDS IN THE EMERGENCE OF 
NEW PSYCHOACTIVE SUBSTANCES 
NPS continue to be a challenge in the region. As of December 
2020, a total of 217 individual substances have been reported 
by 16 countries209 in Latin America and the Caribbean com-
pared to only 101 substances reported by 10 countries in 
2014, the year of publication of the last regional report. 210 
However, not all of these 217 substances are present on the 
illicit drug market at the same time. Thus, the number of 
 different NPS reported per year has never exceeded 72 
 substances since the start of monitoring in 2009. 
Figure 28 .  New psychoactive substances 
reported annually to UNODC in 
Latin America and the Caribbean, 
by effect group, 2015-2020* 
(as of December 2020)
Source: UNODC, Early Warning Advisory on NPS .
Note: Sixteen reporter countries included . 
*Data for 2020 are preliminary .
Between 2015 and 2020, the NPS with stimulant effects 
have been the most frequently reported group from the 
region with 40 per cent followed by the NPS with 
209 Argentina, Bolivia (Plurinational State of), Brazil, Chile, Colombia, 
Costa Rica, Ecuador, El Salvador, Guatemala, Jamaica, Mexico, Panama, 
Paraguay, Peru, Trinidad and Tobago and Uruguay.
210 UNODC, Early Warning Advisory on NPS.
hallucinogenic effects (29 per cent) and synthetic 
 cannabinoid receptor agonist (15 per cent).211
NPS use in the region may be underreported as they are not 
yet regularly included in drug use surveys in the region. In 
addition, they may be sold under the name of other drugs, 
for example NPS with hallucinogenic effects such as “LSD” 
and NPS with stimulant effects such as “ecstasy”, without 
drug users necessarily being aware that they are using NPS. 
Furthermore, some countries in the region may have only 
limited forensic capacity to identify NPS.212,213
Similar to other regions, the number of countries in Latin 
America and the Caribbean which have identified NPS 
continues to increase, as well as the number of different 
NPS reported. 
Figure 29 .  Number of different new 
 psychoactive substances reported 
by Latin American and Caribbean 
countries (as of December 2020)
211 UNODC, Early Warning Advisory on NPS.
212 Organization of American States/Inter-American Drug Abuse 
Control Commission, Emerging Drugs in the Americas: New Psychoactive 
Substances, including Synthetic Opioids (October 2020). 
213 Colombia, Observatorio de Drogas de Colombia, Aparición de Nuevas 














































Source: UNODC, Early Warning Advisory on NPS .
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8 .  LEGAL RESPONSES TO NEW 
PSYCHOACTIVE SUBSTANCES
At the time of writing, information on legal responses to 
the emergence of NPS was available for nine countries in 
Latin America and the Caribbean, namely Argentina, 
Brazil, Chile, Colombia, Costa Rica, Mexico, Nicaragua, 
Trinidad and Tobago and Uruguay.214 The legal approaches 
taken included drug laws/individual listing, early warning 
systems and generic legislation.
214 UNODC, Early Warning Advisory on NPS.
Figure 30 .  Legal approaches to new 
 psychoactive substances in Latin 
American and Caribbean countries
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